51
|
Choi YH, Ha EJ, Shim Y, Kim J, Choo YH, Kim HS, Lee SH, Kim KM, Cho WS, Kang HS, Kim JE. Clinical Outcome of Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage with Bundled Treatments: A Propensity Score-Matched Analysis. Neurocrit Care 2024; 40:177-186. [PMID: 37610642 DOI: 10.1007/s12028-023-01818-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 07/20/2023] [Indexed: 08/24/2023]
Abstract
BACKGROUND Poor-grade aneurysmal subarachnoid hemorrhage (aSAH), defined as Hunt and Hess (HH) grades IV and V, is a challenging disease because of its high mortality and poor functional outcomes. The effectiveness of bundled treatments has been demonstrated in critical diseases. Therefore, poor-grade aSAH bundled treatments have been established. This study aims to evaluate whether bundled treatments can improve long-term outcomes and mortality in patients with poor-grade aSAH. METHODS This is a comparative study using historical control from 2008 to 2022. Bundled treatments were introduced in 2017. We compared the rate of favorable outcomes (modified Rankin Scale score 0-2) at 6 months and mortality before and after the introduction of the bundled treatments. To eliminate confounding bias, the propensity score matching method was used. RESULTS A total of 90 consecutive patients were evaluated. Forty-three patients received bundled treatments, and 47 patients received conventional care. The proportion of patients with HH grade V was higher in the bundle treatment group (41.9% vs. 27.7%). Conversely, the proportion of patients with fixed pupils on the initial examination was higher in the conventional group (30.2% vs. 38.3%). After 1:1 propensity score matching, 31 pairs were allocated to each group. The proportion of patients with 6-month favorable functional outcomes was significantly higher in the bundled treatments group (46.4% vs. 20.7%, p = 0.04). The 6-month mortality rate was 14.3% in the bundled treatments group and 27.3% in the conventional group (p = 0.01). Bundled treatments (odd ratio 14.6 [95% confidence interval 2.1-100.0], p < 0.01) and the presence of an initial pupil reflex (odd ratio 12.0 [95% confidence interval 1.4-104.6], p = 0.02) were significantly associated with a 6-month favorable functional outcome. CONCLUSIONS The bundled treatments improve 6-month functional outcome and mortality in patients with poor-grade aSAH.
Collapse
Affiliation(s)
- Young Hoon Choi
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Eun Jin Ha
- Department of Critical Care Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro Jongno-gu, Seoul, 03080, Republic of Korea.
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea.
| | - Youngbo Shim
- Department of Critical Care Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro Jongno-gu, Seoul, 03080, Republic of Korea
| | - Jungook Kim
- Department of Critical Care Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro Jongno-gu, Seoul, 03080, Republic of Korea
| | - Yoon-Hee Choo
- Department of Neurosurgery, Seoul St. Mary's Hospital and College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Hye Seon Kim
- Department of Neurosurgery, Incheon St. Mary's Hospital and College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea
| | - Sung Ho Lee
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
- Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| | - Kang Min Kim
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
- Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| | - Won-Sang Cho
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
- Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| | - Hyun-Seung Kang
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
- Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| | - Jeoug Eun Kim
- Department of Neurosurgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
- Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
52
|
Thapa P, Bhattarai G, Kharel SK, Kunwar P, Bhandari S, Bhandari S, Shilpakar S, Thapa B, Thapa A, Sharma MR. Endovascular treatment of subdural haematoma in patient under anti-platelet therapy: a case report. Ann Med Surg (Lond) 2024; 86:1066-1071. [PMID: 38333269 PMCID: PMC10849360 DOI: 10.1097/ms9.0000000000001516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Accepted: 11/06/2023] [Indexed: 02/10/2024] Open
Abstract
Introduction The incidence of chronic subdural haematoma (cSDH) is relatively high among the elderly population. Other known risk factors for cSDH include male sex, dependency on anti-platelet or anticoagulant medication, and chronic alcoholism. Although, the standard mode of treatment for cSDH is surgery, embolization of the middle meningeal artery (MMA), either upfront or as an adjunct to surgical evacuation can be used for the treatment of cSDH. Case presentation The authors present a case of a 75-year-old female with prior history of posterior-lateral wall myocardial infarction (MI) eight years back presented to our centre with the chief complaints of a gradual onset of cough and headache for 2 months. The patient had no history of trauma, loss of consciousness, seizures, and vomiting. There was no history of diabetes, hypertension, pulmonary tuberculosis, and other chronic illness. Discussion The concurrent use of anti- platelet drug during a surgical procedure can make the treatment challenging. Endovascular treatment can be a primary treatment modality in such situation. Conclusion Elimination of blood supply by middle meningeal artery embolization is emerging as a safe, minimally invasive alternative to treat cSDH.
Collapse
Affiliation(s)
| | - Ganesh Bhattarai
- Maharajgunj Medical Campus, Tribhuvan University, Institute of Medicine, Maharajgunj
| | - Santosh Kumar Kharel
- Maharajgunj Medical Campus, Tribhuvan University, Institute of Medicine, Maharajgunj
| | | | | | - Shailaj Bhandari
- Nepal Medical College Teaching Hospital, Jorpati, Katmandu, Nepal
| | | | | | | | | |
Collapse
|
53
|
Qiao Y, Zhang YJ, Tsappidi S, Mehta TI, Hui FK. Direct superficial temporal artery access for middle meningeal artery embolization. Interv Neuroradiol 2024:15910199231225832. [PMID: 38196319 DOI: 10.1177/15910199231225832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2024] Open
Abstract
Middle meningeal artery embolization has become an important option in the management of subdural hemorrhages with multiple prospective studies demonstrating efficacy and randomized controlled trial data on the way. Access to the middle meningeal artery is usually achieved via the external carotid artery to the internal maxillary artery, then the middle meningeal artery. We report a case where a patient with symptomatic left-sided chronic subdural hemorrhage also had an external carotid artery occlusion. Direct puncture of the superficial temporal artery allowed retrograde access to the internal maxillary artery and thus the middle meningeal artery. Successful embolization of the vessel with 1:9 nBCA was performed with near total resorption of the subdural collection by 1 month postprocedure.
Collapse
Affiliation(s)
- Yang Qiao
- Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, TX, USA
- Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Neurointerventional Surgery, The Queen's Health System, Honolulu, HI, USA
| | - Yi Jonathan Zhang
- Department of Neurointerventional Surgery, The Queen's Health System, Honolulu, HI, USA
| | - Samuel Tsappidi
- Department of Neurointerventional Surgery, The Queen's Health System, Honolulu, HI, USA
| | - Tej I Mehta
- Department of Radiology and Radiological Science, Johns Hopkins Medicine, Baltimore, MD, USA
| | - Ferdinand K Hui
- Department of Neurointerventional Surgery, The Queen's Health System, Honolulu, HI, USA
| |
Collapse
|
54
|
Champeaux Depond C, El Hairech D, Metellus P. Super acute subdural hematoma following drain removal for chronic subdural haematoma. Neurochirurgie 2024; 70:101510. [PMID: 37976803 DOI: 10.1016/j.neuchi.2023.101510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 10/31/2023] [Indexed: 11/19/2023]
Affiliation(s)
- Charles Champeaux Depond
- Department of Neurosurgery, Clairval Private Hospital, 317 Bd du Redon, 13 009 Marseille, France.
| | - Dahmane El Hairech
- Department of Neurosurgery, Clairval Private Hospital, 317 Bd du Redon, 13 009 Marseille, France
| | - Philippe Metellus
- Department of Neurosurgery, Clairval Private Hospital, 317 Bd du Redon, 13 009 Marseille, France; Institut de Neurophysiopathologie - CNRS UMR 7051, Aix-Marseille Université, Marseille, France
| |
Collapse
|
55
|
Akamatsu Y, Kashimura H, Kojima D, Yoshida J, Chika K, Komoribayashi N, Fujiwara S, Ogasawara K. Correlation Between Low-Density Hematoma at 1-Week Post-Middle Meningeal Artery Embolization and Rapid Resolution of Chronic Subdural Hematoma. World Neurosurg 2024; 181:e1088-e1092. [PMID: 37979682 DOI: 10.1016/j.wneu.2023.11.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 11/20/2023]
Abstract
BACKGROUND Temporal changes in the volume of chronic subdural hematoma (CSDH) following middle meningeal artery (MMA) embolization vary. We aimed to determine whether CSDH density on computed tomography is related to hematoma resolution following particle MMA embolization. METHODS Patients who underwent MMA embolization for CSDH were enrolled. The CSDHs were quantitatively divided into 2 hematoma groups based on the hematoma density at 1-week postembolization: low-density or high-density. The temporal change in the volume of CSDHs was then analyzed between the groups. RESULTS Thirty patients were enrolled in this study. Three patients with high-density hematomas required rescue surgery. The hematoma volume was significantly lower in low-density hematomas than in high-density hematoma at 1-week (P = 0.006), 1-month (P = 0.003), and 2-month (P = 0.004) postembolization; although the volume converged to a similar value at 3-month (P > 0.05). There was a positive correlation between hematoma density at 1-week postembolization and percentage hematoma volume at 1-week and 1-month postembolization (P = 0.004 and P < 0.001, respectively), but no correlation was observed between hematoma density before MMA embolization and percentage hematoma volume at 1-week and 1-month postembolization (P = 0.54 and P = 0.17, respectively). CONCLUSIONS Rapid resolution of CSDH following MMA embolization was associated with low hematoma density at 1-week postembolization. Based on hematoma density on computed tomography at 1-week postembolization, a 1-month follow-up would be sufficient in cases of low density, but a 3-month follow-up would be required in cases of high-density hematoma. Larger studies and clinical trials are needed to confirm our findings.
Collapse
Affiliation(s)
- Yosuke Akamatsu
- Department of Neurosurgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan; Department of Neurosurgery, Iwate Prefectural Chubu Hospital, Kitakami, Iwate, Japan.
| | - Hiroshi Kashimura
- Department of Neurosurgery, Iwate Prefectural Chubu Hospital, Kitakami, Iwate, Japan
| | - Daigo Kojima
- Department of Neurosurgery, Iwate Prefectural Chubu Hospital, Kitakami, Iwate, Japan
| | - Jun Yoshida
- Department of Neurosurgery, Iwate Prefectural Chubu Hospital, Kitakami, Iwate, Japan
| | - Kohei Chika
- Department of Neurosurgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| | - Nobukazu Komoribayashi
- Iwate Prefectural Advanced Critical Care and Emergency Center, Iwate Medical University, Yahaba, Japan
| | - Shunrou Fujiwara
- Department of Neurosurgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| | - Kuniaki Ogasawara
- Department of Neurosurgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| |
Collapse
|
56
|
Shetova IM, Lukyanchikov VA, Shatokhin TA, Yakovlev AA, Piradov MA, Krylov VV. [The effect of surgical technique on the long-term results of treatment of brain aneurysms]. Zh Nevrol Psikhiatr Im S S Korsakova 2024; 124:62-70. [PMID: 39269298 DOI: 10.17116/jnevro202412408162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/15/2024]
Abstract
OBJECTIVE To study the long-term outcomes of surgical treatment of cerebral aneurysms (CA) after using different methods of excluding the aneurysm from the bloodstream. MATERIAL AND METHODS We analyzed the long-term results of surgical treatment of 311 patients for CA (on average after 3.5 years). Two hundred and one patients were operated after CA rupture, 110 for an unruptured aneurysm. Microsurgical or endovascular methods were used to isolate the aneurysm from the bloodstream. Upon admission to the hospital for surgical treatment, a clinical diagnostic examination was performed to confirm the diagnosis and determine the timing and type of intervention. In the long-term period, a clinical neurological study, including an assessment of disability with the Barthel index and the modified Rankin scale, cognitive functions (MoCA test) and the psycho-emotional sphere (HADS) was carried out. RESULTS In the long-term period of aneurysm surgery, symptoms of disability were identified in 49 patients (16%), severe and complete limitation of self-care in 17 (8%), and cognitive impairment in 212 (68%). Endovascular embolization performance of an aneurysm was associated with a higher proportion of favorable functional outcomes compared with the use of a microsurgical method (10% versus 17%), as well as preservation of cognitive functions (9% and 17%, respectively). Blood clots fibrinolysis was associated with severe disability and dependence in the long-term period (p=0.04). Patients treated with extra-intracranial shunting (EICS) demonstrated better cognitive functions; fibrinolysis, on the contrary, was a predictor of dementia (p=0.02). There was no relationship between symptoms of anxiety and depression in the long-term period and surgical treatment method. CONCLUSIONS Disability, dependence and disturbance of cognitive functions in the long-term period of CA surgical treatment are higher in patients after microsurgical clipping compared to endovascular embolization. Performance of blood clots fibrinolysis is associated with severe disability and dementia in patients with massive basal aneurysmal subarachnoid hemorrhage. Performing EICS is associated with a favorable prognosis for the recovery of cognitive functions.
Collapse
Affiliation(s)
- I M Shetova
- Scientific Center of Neurology, Moscow, Russia
- Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - V A Lukyanchikov
- Scientific Center of Neurology, Moscow, Russia
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - T A Shatokhin
- Scientific Center of Neurology, Moscow, Russia
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - A A Yakovlev
- Institute of Higher Nervous Activity and Neurophysiology, Moscow, Russia
| | - M A Piradov
- Scientific Center of Neurology, Moscow, Russia
| | - V V Krylov
- Pirogov Russian National Research Medical University, Moscow, Russia
| |
Collapse
|
57
|
Dinc R. Featured minimally invasive therapeutic approach for chronic subdural hematoma: Embolization of middle meningeal artery - A narrative review. Brain Circ 2024; 10:28-34. [PMID: 38655446 PMCID: PMC11034447 DOI: 10.4103/bc.bc_65_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/29/2023] [Accepted: 11/10/2023] [Indexed: 04/26/2024] Open
Abstract
Chronic subdural hematoma (c-SDH) is a frequent and serious neurological disease. It develops due to hemorrhage to the subdural space, mainly caused by head trauma. The middle meningeal artery (MMA) plays a critical role in the supply of blood to c-SDH. The decision on the type of treatment for c-SDH depends mainly on clinical and imaging evaluation. In cases in which patients are critically ill, the hematoma must be evacuated immediately. For this purpose, surgery is generally accepted as the mainstay of treatment. Among surgical techniques, twist-drill craniotomy, burr-hole craniotomy, and craniotomy are the three most used. The recurrence rate of c-SDH after surgery is an important problem with a rate of up to 30%. The technical success classification embolization of MMA (EMMA) has emerged as an effective and safe option for the treatment of c-SDH, especially those that recur. EMMA is commonly used as an adjunct to surgery or less frequently alone. The technical success of EMMA has been a promising minimal invasive strategy as an alternative or adjunctive therapy to surgical methods. Polyvinyl alcohol is the most widely used among various embolizing agents, including n-butyl cyanoacrylate, coil, and gelatin sponge. EMMA has been shown to prevent the formation or recurrence of c-SDH by eliminating blood flow to the subdural space. Complication rates are low. The large-scale comparative prospective will ensure efficacy and safety. This article aims to highlight the current information about EMMA in patients with c-SDH.
Collapse
Affiliation(s)
- Rasit Dinc
- Department of Research and Development, INVAMED Medical Innovation Institute, Ankara/Turkey
| |
Collapse
|
58
|
Sinha S, Kalyal N, Gallagher MJ, Richardson D, Kalaitzoglou D, Abougamil A, Silva M, Oviedova A, Patel S, Mirallave-Pescador A, Bleil C, Zebian B, Gullan R, Ashkan K, Vergani F, Bhangoo R, Pedro Lavrador J. Impact of Preoperative Mapping and Intraoperative Neuromonitoring in Minimally Invasive Parafascicular Surgery for Deep-Seated Lesions. World Neurosurg 2024; 181:e1019-e1037. [PMID: 37967744 DOI: 10.1016/j.wneu.2023.11.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 11/07/2023] [Indexed: 11/17/2023]
Abstract
BACKGROUND Transsulcal tubular retractor-assisted minimally invasive parafascicular surgery changes the surgical strategy for deep-seated lesions by promoting a deficit-sparing approach. When integrated with preoperative brain mapping and intraoperative neuromonitoring (IONM), this approach may potentially improve patient outcomes. In this study, we assessed the impact of preoperative brain mapping and IONM in tubular retractor-assisted neuro-oncological surgery. METHODS This retrospective single-center cohort study included patients who underwent transsulcal tubular retractor-assisted minimally invasive parafascicular surgery for resection of deep-seated brain tumors from 2016 to 2022. The cohort was divided into 3 groups: group 1, no preoperative mapping or IONM (17 patients); group 2, IONM only (25 patients); group 3, both preoperative mapping and IONM (38 patients). RESULTS We analyzed 80 patients (33 males and 47 females) with a median age of 46.5 years (range: 1-81 years). There was no significant difference in mean tumor volume (26.2 cm3 [range 1.07-97.4 cm3]; P = 0.740) and mean preoperative depth of the tumor (31 mm [range 3-65 mm], P = 0.449) between the groups. A higher proportion of high-grade gliomas and metastases was present within group 3 (P = 0.003). IONM was related to fewer motor (P = 0.041) and language (P = 0.032) deficits at hospital discharge. Preoperative mapping and IONM were also related to shorter length of stay (P = 0.008). CONCLUSIONS Preoperative and intraoperative brain mapping and monitoring enhance transsulcal tubular retractor-assisted minimally invasive parafascicular surgery in neuro-oncology. Patients had a reduced length of stay and prolonged overall survival. IONM alone reduces postoperative neurological deficit.
Collapse
Affiliation(s)
- Siddharth Sinha
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom.
| | - Nida Kalyal
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Mathew J Gallagher
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Daniel Richardson
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Dimitrios Kalaitzoglou
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Ahmed Abougamil
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Melissa Silva
- Department of Neurosurgery, Intraoperative Neurophysiology, King's College Hospital Foundation Trust, London, United Kingdom
| | - Anna Oviedova
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Sabina Patel
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Ana Mirallave-Pescador
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom; Departamento de Neurocirurgia, Hospital Garcia de Orta, Almada, Portugal
| | - Cristina Bleil
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Bassel Zebian
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Richard Gullan
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Keyoumars Ashkan
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Francesco Vergani
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - Ranjeev Bhangoo
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| | - José Pedro Lavrador
- Department of Neurosurgery, King's College Hospital Foundation Trust, London, United Kingdom
| |
Collapse
|
59
|
Naldi A, Pracucci G, Cavallo R, Saia V, Boghi A, Lochner P, Casetta I, Sallustio F, Zini A, Fainardi E, Cappellari M, Tassi R, Bracco S, Bigliardi G, Vallone S, Nencini P, Bergui M, Mangiafico S, Toni D. Mechanical thrombectomy for in-hospital stroke: data from the Italian Registry of Endovascular Treatment in Acute Stroke. J Neurointerv Surg 2023; 15:e426-e432. [PMID: 36882319 DOI: 10.1136/jnis-2022-019939] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 02/25/2023] [Indexed: 03/09/2023]
Abstract
BACKGROUND The benefit, safety, and time intervals of mechanical thrombectomy (MT) in patients with in-hospital stroke (IHS) are unclear. We sought to evaluate the outcomes and treatment times for IHS patients compared with out-of-hospital stroke (OHS) patients receiving MT. METHODS We analyzed data from the Italian Registry of Endovascular Treatment in Acute Stroke (IRETAS) between 2015 and 2019. We compared the functional outcomes (modified Rankin Scale (mRS) scores) at 3 months, recanalization rates, and symptomatic intracranial hemorrhage (sICH) after MT. Time intervals from stroke onset-to-imaging, onset-to-groin, and onset-to-end MT were recorded for both groups, as were door-to-imaging and door-to-groin for OHS. A multivariate analysis was performed. RESULTS Of 5619 patients, 406 (7.2%) had IHS. At 3 months, IHS patients had a lower rate of mRS 0-2 (39% vs 48%, P<0.001) and higher mortality (30.1% vs 19.6%, P<0.001). Recanalization rates and sICH were similar. Time intervals (min, median (IQR)) from stroke onset-to-imaging, onset-to-groin, and onset-to-end MT were favorable for IHS (60 (34-106) vs 123 (89-188.5); 150 (105-220) vs 220 (168-294); 227 (164-303) vs 293 (230-370); all P<0.001), whereas OHS had lower door-to-imaging and door-to-groin times compared with stroke onset-to-imaging and onset-to-groin for IHS (29 (20-44) vs 60 (34-106), P<0.001; 113 (84-151) vs 150 (105-220); P<0.001). After adjustment, IHS was associated with higher mortality (aOR 1.77, 95% CI 1.33 to 2.35, P<0.001) and a shift towards worse functional outcomes in the ordinal analysis (aOR 1.32, 95% CI 1.06 to 1.66, P=0.015). CONCLUSION Despite favorable time intervals for MT, IHS patients had worse functional outcomes than OHS patients. Delays in IHS management were detected.
Collapse
Affiliation(s)
- Andrea Naldi
- Neurology Unit, Ospedale San Giovanni Bosco, Torino, Piemonte, Italy
| | - Giovanni Pracucci
- Department of NEUROFARBA, Neuroscience Section, University of Florence, Florence, Italy
| | - Roberto Cavallo
- Neurology Unit, Ospedale San Giovanni Bosco, Torino, Piemonte, Italy
| | - Valentina Saia
- Neurology and Stroke Unit, Santa Corona Hospital, Pietra Ligure, Italy
| | - Andrea Boghi
- Radiology and Neuroradiology Unit, San Giovanni Bosco Hospital, Turin, Italy
| | - Piergiorgio Lochner
- Department of Neurology, Saarland University Medical Center, University of the Saarland, Homburg, Germany
| | - Ilaria Casetta
- Neurology Unit, University Hospital Arcispedale S. Anna, Ferrara, Italy
| | - Fabrizio Sallustio
- Unità di Trattamento Neurovascolare, Ospedale dei Castelli-ASL6, Rome, Italy
| | - Andrea Zini
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - Enrico Fainardi
- Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Neuroradiologia, Università degli Studi di Firenze, Ospedale Universitario Careggi, Florence, Italy
| | - Manuel Cappellari
- Stroke Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Rossana Tassi
- Stroke Unit, Ospedale S. Maria Delle Scotte-University Hospital, Siena, Italy
| | - Sandra Bracco
- UO Neurointerventistica, Ospedale S. Maria Delle Scotte-University Hospital, Siena, Italy
| | - Guido Bigliardi
- Neurologia/Stroke Unit, Ospedale Civile di Baggiovara, AOU Modena, Modena, Italy
| | - Stefano Vallone
- Neuroradiologia, Ospedale Civile di Baggiovara, AOU Modena, Modena, Italy
| | - Patrizia Nencini
- Stroke Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Mauro Bergui
- Interventional Neuroradiology Unit, Città della Salute e della Scienza - Molinette, Turin, Italy
| | - Salvatore Mangiafico
- Interventional Neuroradiology Consultant at IRCCS Neuromed, Pozzilli (IS), and Adjunct Professor of Interventional Neuroradiology at Tor Vergata University, Sapienza University and S. Andrea Hospital, Rome, Italy
| | - Danilo Toni
- Emergency Department Stroke Unit, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
60
|
Abdulrazeq H, Leary OP, Tang OY, Karimi H, McElroy A, Gokaslan Z, Punsoni M, Donahue JE, Klinge PM. The Surgical Histopathology of the Filum Terminale: Findings from a Large Series of Patients with Tethered Cord Syndrome. J Clin Med 2023; 13:6. [PMID: 38202013 PMCID: PMC10779556 DOI: 10.3390/jcm13010006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 12/16/2023] [Accepted: 12/17/2023] [Indexed: 01/12/2024] Open
Abstract
This study investigated the prevalence of embryonic and connective tissue elements in the filum terminale (FT) of patients with tethered cord syndrome (TCS), examining both typical and pathological histology. The FT specimens from 288 patients who underwent spinal cord detethering from 2013 to 2021 were analyzed. The histopathological examination involved routine hematoxylin and eosin staining and specific immunohistochemistry when needed. The patient details were extracted from electronic medical records. The study found that 97.6% of the FT specimens had peripheral nerves, and 70.8% had regular ependymal cell linings. Other findings included ependymal cysts and canals, ganglion cells, neuropil, and prominent vascular features. Notably, 41% showed fatty infiltration, and 7.6% had dystrophic calcification. Inflammatory infiltrates, an underreported finding, were observed in 3.8% of the specimens. The research highlights peripheral nerves and ganglion cells as natural components of the FT, with ependymal cell overgrowth and other tissues potentially linked to TCS. Enlarged vessels may suggest venous congestion due to altered FT mechanics. The presence of lymphocytic infiltrations and calcifications provides new insights into structural changes and mechanical stress in the FT, contributing to our understanding of TCS pathology.
Collapse
Affiliation(s)
- Hael Abdulrazeq
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Department of Neurosurgery, Rhode Island Hospital, Providence, RI 02903, USA
| | - Owen P. Leary
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Department of Neurosurgery, Rhode Island Hospital, Providence, RI 02903, USA
| | - Oliver Y. Tang
- Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; (O.Y.T.)
| | - Helen Karimi
- Department of Neurosurgery, Tufts Medical School, Boston, MA 02111, USA;
| | - Abigail McElroy
- Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; (O.Y.T.)
| | - Ziya Gokaslan
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Department of Neurosurgery, Rhode Island Hospital, Providence, RI 02903, USA
| | - Michael Punsoni
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Laboratory Medicine, Department of Pathology, Rhode Island Hospital, Providence, RI 02903, USA
| | - John E. Donahue
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Department of Neurosurgery, Rhode Island Hospital, Providence, RI 02903, USA
- Laboratory Medicine, Department of Pathology, Rhode Island Hospital, Providence, RI 02903, USA
| | - Petra M. Klinge
- Department of Neurosurgery, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA; (O.P.L.); (J.E.D.)
- Department of Neurosurgery, Rhode Island Hospital, Providence, RI 02903, USA
| |
Collapse
|
61
|
Woo SB, Ko YS, Lee CY. Iatrogenic mixed pial and dural arteriovenous fistula after pterional approach for surgical clipping of aneurysm: A case report. J Cerebrovasc Endovasc Neurosurg 2023; 25:440-446. [PMID: 37189252 PMCID: PMC10774680 DOI: 10.7461/jcen.2023.e2022.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2022] [Revised: 02/21/2023] [Accepted: 04/23/2023] [Indexed: 05/17/2023] Open
Abstract
Craniotomy is known as a cause of iatrogenic dural cerebral arteriovenous fistula (AVF). However, mixed pial and dural AVFs after craniotomy are extremely rare and require accurate diagnosis and prompt treatment due to their aggressiveness. We present a case of an iatrogenic mixed pial and dural AVF diagnosed 2 years after pterional craniotomy for surgical clipping of a ruptured anterior choroidal aneurysm. The lesion was successfully treated using single endovascular procedure of transvenous coil embolization through the engorged vein of Labbe and the superficial middle cerebral vein. The possibility of the AVF formation after the pterional approach should always be kept in mind because it usually occurs at the middle cranial fossa, which frequently has an aggressive nature owing to direct cortical venous or leptomeningeal drainage patterns. This complication is believed to be caused by angiogenetic conditions due to coagulation, retraction, and microinjuries of the perisylvian vessels, and can be prevented by performing careful sylvian dissection according to patient-specific perisylvian venous anatomy.
Collapse
Affiliation(s)
- Seung-Bin Woo
- Department of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
| | - Young San Ko
- Department of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
| | - Chang-Young Lee
- Department of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
| |
Collapse
|
62
|
Tong X, Xue X, Liu A, Qi P. Comparative study on clinical outcomes and cost-effectiveness of chronic subdural hematomas treated by middle meningeal artery embolization and conventional treatment: a national cross-sectional study. Int J Surg 2023; 109:3836-3847. [PMID: 37830938 PMCID: PMC10720801 DOI: 10.1097/js9.0000000000000699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 08/13/2023] [Indexed: 10/14/2023]
Abstract
BACKGROUND The authors compared the efficacy and cost-effectiveness of middle meningeal artery embolization (MMAE) and conventional treatment for chronic subdural hematomas (cSDH). METHODS The Nationwide Readmissions Database of 9963 patients (27.2% women) with cSDH between 2016 and 2020 was analyzed. Finally, 9532 patients were included (95.7%, treated conventionally; 4.3%, treated with MMAE). Baseline demographics, comorbidities, adverse events, treatment strategies, and outcomes were compared between patients treated with MMAE and conventional treatment. After propensity score matching, the authors compared primary outcomes, including the 90-day treatment rate, functional outcome, length of hospital stays, and cost. A Markov model estimated lifetime costs and quality-adjusted life years (QALYs) associated with different treatments. The incremental cost-effectiveness ratio (ICER) was calculated to evaluate the base-case scenario. One-way, two-way, and probabilistic sensitivity analyses were performed to evaluate the uncertainty in the results. RESULTS After propensity score matching, MMAE had a lower 90-day retreatment rate (2.6 vs. 9.0%, P =0.001), shorter length of hospital stays (4.61±6.19 vs. 5.73±5.76 days, P =0.037), similar functional outcomes compared (favorable outcomes, 80.9 vs. 74.8%, P =0.224) but higher costs ($119 757.71±90 378.70 vs. $75 745.55±100 701.28, P <0.001) with conventional treatment. MMAE was associated with an additional cost of US$19 280.0 with additional QALY of 1.3. Its ICER was US$15199.8/QALY. CONCLUSION MMAE is more effective in treating cSDH than conventional treatment. Based on real-world data, though MMAE incurs higher overall costs, the Markov model showed it to be cost-effective compared to conventional treatment under the American healthcare system. These comparative and economic analyses further support the consideration of a paradigm shift in cSDH treatment.
Collapse
Affiliation(s)
- Xin Tong
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
| | - Xiaopeng Xue
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
| | - Aihua Liu
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
| | - Peng Qi
- Department of Neurosurgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China
| |
Collapse
|
63
|
Rickard F, Gale J, Williams A, Shipway D. New horizons in subdural haematoma. Age Ageing 2023; 52:afad240. [PMID: 38167695 DOI: 10.1093/ageing/afad240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Indexed: 01/05/2024] Open
Abstract
Subdural haematoma (SDH) is a common injury sustained by older people living with frailty and multimorbidity, and typically following falls from a standing height. Anticoagulant and antiplatelet use are commonly indicated in older people with SDH, but few data inform decision-making surrounding these agents in the context of intracranial bleeding. Opposing risks of rebleeding and thrombosis must therefore be weighed judiciously. Decision-making can be complex and requires detailed awareness of the epidemiology to ensure the safest course of action is selected for each patient. Outcomes of surgical decompression in acute SDH are very poor in older people. However, burr hole drainage can be safe and effective in older adults with symptomatic chronic SDH (cSDH). Such patients need careful assessment to ensure symptoms arise from cSDH and not from coexisting medical pathology. Furthermore, the emerging treatment of middle meningeal artery embolisation offers a well-tolerated, minimally invasive intervention which may reduce the risks of rebleeding in older adults. Nonetheless, UK SDH management is heterogenous, and no accepted UK or European guidelines exist at present. Further randomised trial evidence is required to move away from clinical practice based on historic observational data.
Collapse
Affiliation(s)
- Frances Rickard
- Consultant Geriatrician, Geriatric Major Trauma, North Bristol NHS Trust, Bristol, UK
| | - John Gale
- Clinical Fellow in Geriatric Major Trauma, North Bristol NHS Trust, Bristol, UK
| | - Adam Williams
- Consultant Neurosurgeon, Department of Neurosurgery, North Bristol NHS Trust, Bristol, UK
| | - David Shipway
- Consultant Geriatrician, Geriatric Major Trauma, North Bristol NHS Trust, Bristol, UK
- Honorary Senior Clinical Lecturer, University of Bristol, Bristol, UK
| |
Collapse
|
64
|
McCann CP, Brandel MG, Wali AR, Steinberg JA, Pannell JS, Santiago-Dieppa DR, Khalessi AA. Safety of middle meningeal artery embolization for treatment of subdural hematoma: A nationwide propensity score matched analysis. J Cerebrovasc Endovasc Neurosurg 2023; 25:380-389. [PMID: 37469029 PMCID: PMC10774674 DOI: 10.7461/jcen.2023.e2023.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 07/21/2023] Open
Abstract
OBJECTIVE Middle meningeal artery embolization (MMAe) has burgeoned as a treatment for chronic subdural hematoma (cSDH). This study evaluates the safety and short-term outcomes of MMAe patients relative to traditional treatment approaches. METHODS In this retrospective large database study, adult patients in the National Inpatient Sample from 2012-2019 with a diagnosis of cSDH were identified. Cost of admission, length of stay (LOS), discharge disposition, and complications were analyzed. Propensity score matching (PSM) was utilized. RESULTS A total of 123,350 patients with cSDH were identified: 63,450 without intervention, 59,435 surgery only, 295 MMAe only, and 170 surgery plus MMAe. On PSM analysis, MMAe did not increase the risk of inpatient complications or prolong the length of stay compared to conservative management (p>0.05); MMAe had higher cost ($31,170 vs. $10,768, p<0.001) than conservative management, and a lower rate of nonroutine discharge (53.8% vs. 64.3%, p=0.024). Compared to surgery, MMAe had shorter LOS (5 vs. 7 days, p<0.001), and lower rates of neurological complications (2.7% vs. 7.1%, p=0.029) and nonroutine discharge (53.8% vs. 71.7%, p<0.001). There was no significant difference in cost (p>0.05). CONCLUSIONS MMAe had similar LOS and decreased odds of adverse discharge with a modest cost increase compared to conservative management. There was no difference in inpatient complications. Compared to surgery, MMAe treatment was associated with decreased LOS and rates of neurological complications and nonroutine discharge. This nationwide analysis supports the safety of MMAe to treat cSDH.
Collapse
Affiliation(s)
- Carson P. McCann
- Department of Neurosurgery, University of California, San Diego, CA, USA
| | - Michael G. Brandel
- Department of Neurosurgery, University of California, San Diego, CA, USA
| | - Arvin R. Wali
- Department of Neurosurgery, University of California, San Diego, CA, USA
| | | | - J. Scott Pannell
- Department of Neurosurgery, University of California, San Diego, CA, USA
| | | | | |
Collapse
|
65
|
Aziz N, O'Halloran PJ, McKenna GS. Subdural haematoma in the elderly: management and outcomes of a UK Major Trauma Centre. Br J Neurosurg 2023; 37:1604-1612. [PMID: 36218868 DOI: 10.1080/02688697.2022.2122402] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 09/04/2022] [Indexed: 11/02/2022]
Abstract
BACKGROUND An estimated 40% of all traumatic brain injury (TBI) occurs in ≥70-year-olds with a high prevalence of traumatic subdural haematoma (tSDH). It is anticipated that an expanding elderly population will lead to a proportional increase in the incidence of patients with tSDH presenting to UK trauma centres, but the long-term clinical outcomes and factors influencing functional outcomes in this patient group remain poorly understood. AIM To examine the management and clinical outcomes for elderly (≥70 years) patients diagnosed with tSDH. METHODS Patient data for this single-centre, retrospective cohort study were analysed from a Major Trauma Centre (MTC) electronic patient records between January 2013 and December 2019. RESULTS Two hundred and eighty patients were included, 43% aged 70-79, 42% aged 80-89 and 15% >90. In total, 37% underwent a surgical intervention. The 6-month survival in the severe, moderate, and mild TBI groups was 14%, 43%, and 67%, respectively. The 6-month survival in the surgical group was 58%, vs. 60% in the conservatively managed group. Surgical intervention did not significantly impact Extended Glasgow Coma Score (GOS-E) at 6 months, regardless of injury severity. Advanced age (p = 0.04), mixed intracranial injuries (p < 0.0001), craniotomies (p = 0.03), and poor premorbid performance status (p = 0.02) were associated with worse survival and functional outcomes. CONCLUSIONS Our study demonstrated that increasing age, increasing severity of TBI and poorer premorbid performance status were associated with significantly poorer 6-month survival and functional outcomes in elderly patients with tSDH. Burr hole evacuation was associated with better functional outcomes compared to craniotomy, but overall, there was no significant difference in the outcomes of the surgical and non-surgical groups. We identified strong risk factors for death and poor functional outcomes at 6-months which are important to consider when counselling patients and families about the long-term prognosis of elderly patients with tSDH and can help guide clinical decision-making.
Collapse
Affiliation(s)
- Natasha Aziz
- School of Medicine, Queen Mary University of London, London, UK
| | - Philip J O'Halloran
- Department of Neurosurgery, Royal London Hospital, London, UK
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, London, UK
| | | |
Collapse
|
66
|
Wu Z, Wang H, Zhao J, Wang C, Liu H, Wang C, Li A, Hu J. Preoperative Fibrinogen Levels and Function as Predictive Factors for Acute Bleeding in the Hematoma Cavity After Burr Hole Drainage in Patients with CSDH. World Neurosurg 2023; 180:e364-e375. [PMID: 37769840 DOI: 10.1016/j.wneu.2023.09.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 09/18/2023] [Indexed: 10/03/2023]
Abstract
OBJECTIVE Burr hole drainage (BHD) is the primary surgical intervention for managing chronic subdural hematoma (CSDH). However, it can lead to postoperative complications such as acute bleeding within the hematoma cavity and hematoma recurrence. The objective of this study is to identify the risk factors for these complications and develop a predictive model for acute hematoma cavity bleeding after BHD in patients with CSDH. METHODS This study presents a retrospective cohort investigation conducted at a single center. The clinical dataset of 308 CSDH patients who underwent BHD at a hospital from 2016 to 2022 was analyzed to develop and assess a prognostic model. RESULTS The nonbleeding group exhibited a significant correlation between fibrinogen (FIB) and thrombin time (TT), whereas no correlation was observed in the bleeding group. Notably, both FIB and TT were identified as risk factors for postoperative acute bleeding within the hematoma cavity. We developed a prognostic model to predict the occurrence of postoperative acute bleeding within the hematoma cavity after BHD in patients with CSDH. The model incorporated FIB, TT, coronary artery disease, and Glasgow Coma Scale scores. The model exhibited good discrimination (area under the curve: 0.725) and calibration (Hosmer-Leeshawn goodness of fit test: P > 0.1). Furthermore, decision curve analysis demonstrated the potential clinical benefit of implementing this prediction model. CONCLUSIONS The predictive model developed in this study can forecast the risk of postoperative acute bleeding within the hematoma cavity, thus aiding clinicians in selecting the optimal treatment approach for patients with CSDH.
Collapse
Affiliation(s)
- Zejun Wu
- Department of Neurosurgery, Taihe Hospital, Jinzhou Medical University Union Training Base, Shiyan, China; Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
| | - Hui Wang
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
| | - Junshuang Zhao
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
| | - Chaobin Wang
- Department of Neurosurgery, Taihe Hospital, Jinzhou Medical University Union Training Base, Shiyan, China
| | - Haodong Liu
- The First Clinical College, Hubei University of Medicine, Shiyan, China
| | - Chaojia Wang
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
| | - Anrong Li
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
| | - Juntao Hu
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China; Hubei KeyLaboratory of Embryonic Stem Cell Research, Tai-He Hospital, Hubei University of Medicine, Shiyan, China.
| |
Collapse
|
67
|
John K, Syed S, Kaestner T, Dashti R, Fiorella D, Sadasivan C. Liquid embolic surface area as a predictor of chronic subdural hematoma resolution in middle meningeal artery embolization. J Neurointerv Surg 2023:jnis-2023-021118. [PMID: 38050160 DOI: 10.1136/jnis-2023-021118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Accepted: 11/17/2023] [Indexed: 12/06/2023]
Abstract
BACKGROUND Liquid embolic agents (LEAs) such as ethylene vinyl alcohol (EVOH) are utilized for middle meningeal artery embolization (MMAE) for chronic subdural hematomas (cSDH). LEAs may be advantageous for MMAE as they are permanent and can penetrate the microvasculature of the subdural membranes. LEA surface area (SA) can quantify this penetration. The segmentation of LEA SA is not described in the literature and may be of interest in refining MMAE technique. METHODS We retrospectively collected computerized tomography (CT) scans from 74 patients (with 95 cSDH) who underwent first-line MMAE with EVOH. Non-contrast head CTs were acquired pre-embolization, immediately post-embolization and at 1-, 3-, and 6 month follow-up. A 3D-Slicer was used to segment hematoma volumes and the liquid embolic cast. We hypothesized that greater LEA SA would be correlated with greater improvements in cSDH volumetric resolution. RESULTS There was significant resolution in cSDH volumes over the follow-up period compared to preoperative volume (p<0.0001). The LEA SA was significantly correlated with the rate of cSDH resolution at 3 months (R2=0.08, p=0.03), and 6 months (R2=0.14, p=0.01). CONCLUSIONS The correlation of LEA surface area with hematoma resolution at 3-months and 6-months suggests greater LEA penetration may improve radiographic outcomes. This study uniquely provides a quantitative radiological perspective on the effect of LEA penetration on cSDH resolution.
Collapse
Affiliation(s)
- Kevin John
- Department of Radiology, Stony Brook Medicine, Stony Brook, New York, USA
| | - Shoaib Syed
- Department of Neurological Surgery, Stony Brook Medicine, Stony Brook, New York, USA
| | | | - Reza Dashti
- Department of Neurological Surgery, Stony Brook Medicine, Stony Brook, New York, USA
| | - David Fiorella
- Department of Neurological Surgery, Stony Brook Medicine, Stony Brook, New York, USA
| | - Chander Sadasivan
- Department of Neurological Surgery, Stony Brook Medicine, Stony Brook, New York, USA
| |
Collapse
|
68
|
Eun J, Ahn S, Lee MH, Choi JG, Kim YI, Cho CB, Park JS. Potential impact of high-density lipoprotein cholesterol in the postoperative outcomes of chronic subdural hematoma patients: multi-institutional study in Korea. Lipids Health Dis 2023; 22:197. [PMID: 37978499 PMCID: PMC10655259 DOI: 10.1186/s12944-023-01970-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Accepted: 11/13/2023] [Indexed: 11/19/2023] Open
Abstract
BACKGROUND Chronic subdural hematoma (CSDH) is a common clinical situation in neurosurgical practice, but the optimal treatment option is controversial. This study aimed to evaluate the effect of cholesterol-lowering medications on and how they affected the prognoses of CSDH patients. METHODS In this multi-institutional observational study performed in Korea, data from recently treated CSDH patients were gathered from 5 hospitals. A total of 462 patients were collected from March 2010 to June 2021. Patient clinical characteristics, history of underlying diseases and their treatments, radiologic features, and surgical outcomes were analyzed. RESULTS Seventy-five patients experienced recurrences, and 62 had reoperations after the initial burr hole surgery. Among these, 15 patients with recurrences and 12 with reoperations were taking cholesterol-lowering medications. However, the use of medications did not significantly affect recurrence or reoperation rates (P = 0.350, P = 0.336, respectively). When analyzed by type of medication, no clinically relevant differences in total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C) levels were identified. The combination of a statin drug and ezetimibe significantly elevated high-density lipoprotein cholesterol (HDL-C) levels (P = 0.004). TC, LDL-C, and TG levels did not significantly affect patient prognoses. However, HDL-C levels and recurrence (odds ratio (OR) = 0.96; 95% confidence interval (CI): 0.94-0.99; p = 0.010) were negatively correlated. An HDL-C level of 42.50 mg/dL was identified as the threshold for recurrence and reoperation. CONCLUSIONS In this study, using cholesterol-lowering medications did not significantly impact the prognosis of patients who underwent surgical management for a chronic subdural hematoma. However, the findings showed that the higher the HDL-C level, the lower the probability of recurrence and reoperation.
Collapse
Affiliation(s)
- Jin Eun
- Department of Neurosurgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Stephen Ahn
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Min Ho Lee
- Department of Neurosurgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jin-Gyu Choi
- Department of Neurosurgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Young Il Kim
- Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Chul Bum Cho
- Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jae-Sung Park
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
| |
Collapse
|
69
|
Iwasaki M, Naito K, Endo T, Hijikata Y, Mizuno M, Hoshimaru M, Hida K, Takami T. Impact of surgical treatment for intramedullary spinal cord metastasis on neurological function and survival: A multicenter retrospective study by the Neurospinal Society of Japan. J Clin Neurosci 2023; 117:27-31. [PMID: 37740999 DOI: 10.1016/j.jocn.2023.09.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 08/31/2023] [Accepted: 09/16/2023] [Indexed: 09/25/2023]
Abstract
BACKGROUND This retrospective multicenter study aimed to analyze the characteristics and surgical outcomes of intramedullary spinal cord metastasis (ISCM) and to discuss the controversy regarding its surgical indications. METHODS This study included 29 ISCM patients who underwent surgery between 2009 and 2020. Biopsy cases were excluded from analysis. For functional and neurological functional assessments, Karnofsky Performance Status (KPS, %) and modified McCormick Scale (MMS, 5-grade scale) scores were determined before and after surgery. Patients were divided into two groups: a mild-to-moderate disability group with preoperative MMS grades 1 to 3, and a severe disability group with preoperative MMS grades 4 to 5. RESULTS The mean preoperative KPS was 45.9, and the mean duration from symptom onset to surgical intervention was 1 month. The ISCM was located in the cervical spine in 10 cases and the thoracic spine in 19 cases. The access route (myelotomy) for ISCM removal was via the posterior median sulcus in 9 cases and via the posterior lateral sulcus in 11 cases, while others were not recorded. The degree of removal was gross total resection in 20 patients (69%), subtotal resection in 0 patients, and partial removal in 9 patients (31%). No significant complications related to the surgical procedures were recorded. Postoperative adjuvant therapy included radiotherapy in 17 patients (58.6%) and chemotherapy or molecular targeted therapy in 13 patients (44.8%). Pathological findings of ISCM showed that colorectal cancer was the most common in 9 cases, followed by lung cancer in 7, renal cell carcinoma in 5, and breast cancer in 2. Twenty-one of the 29 patients (72.4%) were confirmed to have survived 6 months after surgery: 8 of the 10 patients (80%) in the mild-to-moderate disability group and 13 of the 19 patients (68.4%) in the severe disability group. At 6 months after surgery, 3 of the 8 patients (38%) in the mild-to-moderate group were able to maintain or improve their function. Eleven of the 13 patients (85%) in the severe disability group maintained their function despite being severely disabled. CONCLUSIONS This study suggests that surgical treatment can maintain or improve neurological function in a limited number of patients with ISCM, although it had minimal impact on improving the survival rate after surgery.
Collapse
Affiliation(s)
- Motoyuki Iwasaki
- Department of Neurosurgery, Hokkaido University, Sapporo, Japan.
| | - Kentaro Naito
- Department of Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Toshiki Endo
- Division of Neurosurgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | | | - Masaki Mizuno
- Department of Minimum-Invasive Neurospinal Surgery, Mie University, Mie, Japan
| | | | - Kazutoshi Hida
- Department of Neurosurgery, Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan
| | - Toshihiro Takami
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| |
Collapse
|
70
|
Li M, Wan S, Wang N, Chen J, Duan J, Chen J, Zhang X, Meng R, Ji X. Development and Validation of a Clinical-Based Severity Scale for Patients with Cerebral Venous Thrombosis. Int J Gen Med 2023; 16:4783-4794. [PMID: 37904904 PMCID: PMC10613448 DOI: 10.2147/ijgm.s437457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Accepted: 10/16/2023] [Indexed: 11/01/2023] Open
Abstract
Introduction Cerebral venous thrombosis (CVT) is a rare subtype of stroke. However, existing scales were insufficient to evaluate the overall severity of CVT. The aim of this study is to develop and validate a CVT severity scale. Methods Items 1-11 were directly derived from NIHSS. New items were generated from a literature review and focus group discussion. A total of 170 CVT patients were prospectively recruited from 26 top tertiary hospitals in China Mainland from January 2021 to May 2022 to validate the CVT severity scale. The CVT severity scale, NIHSS, mRS and GCS were rated at admission. The lumbar puncture opening pressure was also recorded. Twenty randomly selected CVT patients were rated with the CVT severity scale again 24 hours later. The clinical outcome of CVT was evaluated by mRS at 6 months after baseline. Results We successfully established a CVT severity scale with 18 items. Exploratory factor analysis showed that 18 items were attributed to factor 1 (focal neurological deficits), factor 2 (diffuse encephalopathy), factor 3 (intracranial hypertension) and factor 4 (cavernous sinus syndrome). CVT severity scale was positively correlated with ICP, NIHSS and mRS, and negatively correlated with GCS at baseline. CVT severity scale >3 or factor 3 >2 indicated intracranial hypertension. CVT severity scale >10 indicated poor clinical outcome at 6 months of follow-up. Meanwhile, CVT severity scale showed high internal consistency and test-retest reliability. Conclusion The CVT severity scale included 18 items encompassing 4 domains of focal neurological deficits, diffuse encephalopathy, IH and cavernous sinus syndrome. CVT severity scale correlated well with ICP, NIHSS, mRS and GCS. Patients with CVT severity scale >10 can be defined as severe CVT. The CVT severity scale may serve as a valid and reliable tool for measuring the overall severity of CVT.
Collapse
Affiliation(s)
- Min Li
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, People’s Republic of China
| | - Shuling Wan
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Nanbu Wang
- Department of Neurology, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China
| | - Jiahao Chen
- Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing, People’s Republic of China
| | - Jiangang Duan
- Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Jian Chen
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Xuxiang Zhang
- Department of Ophthalmology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Ran Meng
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, People’s Republic of China
| | - Xunming Ji
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, People’s Republic of China
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
| |
Collapse
|
71
|
Sioutas GS, Mouchtouris N, Saiegh FA, Naamani KE, Amllay A, Becerril-Gaitan A, Velagapudi L, Gooch MR, Herial NA, Jabbour P, Rosenwasser RH, Tjoumakaris SI. Middle Meningeal Artery Embolization for Subdural Hematoma: An Institutional Cohort and Propensity Score-Matched Comparison with Conventional Management. Clin Neurol Neurosurg 2023; 233:107895. [PMID: 37556969 DOI: 10.1016/j.clineuro.2023.107895] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 08/11/2023]
Abstract
BACKGROUND The treatment of non-acute subdural hematoma (NASDH) is challenging due to its high recurrence rates and comorbidities of mostly elderly patients. Middle meningeal artery embolization (MMAE) recently emerged as an alternative to surgery in the treatment of NASDH. OBJECTIVE To describe a single center's experience of MMAE with Onyx for NASDH and compare it to a surgically treated historical cohort. METHODS We performed a retrospective analysis of patients undergoing MMAE for NASDH from 2019 to 2021. MMAE was performed with ethylene vinyl alcohol copolymer (Onyx). Comparisons were made with a historical cohort from 2010 to 2018 who underwent surgical evacuation only, before and after propensity score matching. Outcomes were assessed clinically and radiographically. RESULTS We included 44 consecutive patients (55 MMAEs) who underwent MMAE, with a median follow-up of 63.5 days. Twenty-four NASDHs underwent upfront embolization, 17 adjunctive, and 14 for recurrence after prior surgical evacuation, with no significant differences in hematoma and mRS reduction between them. Two patients died during hospitalization and 2 during follow-up, unrelated to the procedure. Mean SDH thickness decreased by 48.3% ± 38.1% (P < 0.001) on last follow-up, which did not correlate with the amount of Onyx injected. Six (13.6%) patients required surgical rescue after embolization. There were no procedure-related complications. The mean modified Rankin Scale (mRS) on admission was 2.8 ± 1.5, which decreased significantly to 1 [1,4] at the last follow-up (P = 0.033). The MMAE (41 hematomas; upfront and adjunctive embolization) and Surgical Evacuation-only (461 hematomas) cohorts were balanced with propensity score mathing. Matching was successful for 41 MMAE and 41 surgical-only hematoma pairs, and only hypertension remained significantly different between the two groups, but there was no significant difference in any outcome. CONCLUSION MMAE for NASDH seems safe and effective in appropriately selected patients, non-inferior to surgery, and may become a minimally-invasive alternative. Given our encouraging results, large-scale clinical randomized trials are warranted.
Collapse
Affiliation(s)
- Georgios S Sioutas
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Nikolaos Mouchtouris
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Fadi Al Saiegh
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Kareem El Naamani
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Abdelaziz Amllay
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Andrea Becerril-Gaitan
- Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX, USA
| | - Lohit Velagapudi
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - M Reid Gooch
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Nabeel A Herial
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Pascal Jabbour
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Robert H Rosenwasser
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | | |
Collapse
|
72
|
Hu J, Su F, Ren X, Cao L, Wang C, Mei W, Fang Y, Tavengana G, Jiang M, Wu H, Wen Y. Gender-based relationship between serum creatinine and carotid plaque stability: A cross-sectional study in China. Clin Neurol Neurosurg 2023; 233:107966. [PMID: 37703617 DOI: 10.1016/j.clineuro.2023.107966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Revised: 08/25/2023] [Accepted: 09/06/2023] [Indexed: 09/15/2023]
Abstract
OBJECTIVE Carotid plaque instability is a risk factor for ischemic stroke, and changes in serum creatinine are associated with carotid plaque. However, the relationship between serum creatinine and carotid plaque stability is not well explained. This study aimed to interpret this relationship for clinical treatment of carotid plaque. METHODS A total of 4363 subjects aged 29-86 from December 2013 to December 2018 were included in this study. The stability of carotid plaque was determined based on ultrasound echoes and divided into two groups: carotid plaque stable group and carotid plaque unstable group. The relationship between serum creatinine and carotid plaque stability was determined using curve fitting methods as well as logistic regression. RESULTS After age stratification, there was an inverted U-shaped curve between the stability of right carotid plaque and serum creatinine in males, When serum creatinine levels were less than 84 μmol/L, the probability of carotid plaque instability gradually increased, and the carotid plaque became stable when creatinine levels were greater than 84 μmol/L. The relationship between left carotid female plaque stability and serum creatinine showed a U-shaped curve. When serum creatinine levels were less than 80 μmol/L, the carotid plaque stability stabilized, and the probability increased when creatitine levels were more than 80 μmol/L, as the carotid plaque instability rose. CONCLUSION There was an inverted U-shaped relationship between the stability of carotid plaque in the right carotid artery and serum creatinine in males, and a U-shaped relationship between the stability of carotid plaque in the left carotid artery and serum creatinine in females.
Collapse
Affiliation(s)
- Jian Hu
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Fan Su
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Xia Ren
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Lei Cao
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Chenxu Wang
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Wendan Mei
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Yicheng Fang
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Grace Tavengana
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China
| | - Mingfei Jiang
- School of Clinical Medicine, Wannan Medical College, Wuhu, Anhui Province, China
| | - Huan Wu
- School of Laboratory Medicine, Wannan Medical College, Wuhu, Anhui Province, China
| | - Yufeng Wen
- School of Public Health, Wannan Medical College, Wuhu, Anhui Province, China.
| |
Collapse
|
73
|
Housley SB, Monteiro A, Khawar WI, Donnelly BM, Lian MX, Fritz AG, Waqas M, Cappuzzo JM, Snyder KV, Siddiqui AH, Levy EI, Davies JM. Volumetric resolution of chronic subdural hematomas treated with surgical evacuation versus middle meningeal artery embolization during immediate, early, and late follow up: propensity-score matched cohorts. J Neurointerv Surg 2023; 15:943-947. [PMID: 36137743 DOI: 10.1136/jnis-2022-019427] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 08/26/2022] [Indexed: 11/04/2022]
Abstract
BACKGROUND Literature on volumetric resolution and recurrence over time between surgical evacuation alone (SEA) and standalone middle meningeal artery embolization (MMAE) in comparable chronic subdural hematoma (cSDH) patients is limited. METHODS A retrospective database analysis of cSDH patients managed with either SEA or MMAE was conducted. Propensity-score matching was performed for axial and coronal lengths, maximum diameter, and midline shift. Volumetric measurements at multiple time intervals and recurrence were compared between the groups. RESULTS 48 matched hematoma pairs in patients with similar demographics, comorbidities, medications, and symptoms were obtained. Median volume was significantly lower at 24 hours in the SEA group (12.6 mL vs 52.7 mL, p<0.001) but not at remaining intervals. Median volume reduction was significantly greater in the SEA group at 24 hours (39.1 mL vs 8.8 mL in the MMAE group, p<0.001) and at 3-12 weeks (50.8 mL vs 23.7 mL, p<0.001), but not at remaining intervals. The SEA group had a significantly greater median hematoma resolution rate at 24 hours (39.1 mL/day vs 8.8 mL/day, p<0.001) and 3-12 weeks (1 mL/day vs 0.4 mL/day, p<0.001), but not at remaining intervals. Near-complete resolution at 3-12 weeks and 12-60 weeks was not significantly different between groups. Overall, the recurrence rate was significantly higher in the SEA group (22.9% vs 4.2%, p=0.01). CONCLUSIONS In comparable cSDH patients, SEA resulted in better volumetric outcomes in immediate postoperative and early follow-up periods, as expected. However, this difference was not significant at more distant follow-up intervals. Furthermore, surgical patients experienced a significantly higher rate of recurrence.
Collapse
Affiliation(s)
- Steven B Housley
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Andre Monteiro
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Wasiq I Khawar
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Brianna M Donnelly
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Ming Xia Lian
- University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Alexander G Fritz
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Muhammad Waqas
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Justin M Cappuzzo
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
| | - Kenneth V Snyder
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
- Neurosurgery and Canon Stroke and Vascular Research Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Adnan H Siddiqui
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
- Neurosurgery and Radiology and Canon Stroke and Vascular Research Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Elad I Levy
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
- Neurosurgery and Radiology and Canon Stroke and Vascular Research Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Jason M Davies
- Neurosurgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
- Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA
- Neurosurgery and Bioinformatics and Canon Stroke and Vascular Research Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| |
Collapse
|
74
|
Paudel R, Tunkl C, Shrestha S, Subedi RC, Adhikari A, Thapa L, Gajurel BP, Chandra A, Kharel G, Jalan P, Phuyal S, Pokharel BR, Acharya S, Bogati K, Jha P, Kharbuja N, Gumbinger C. Stroke epidemiology and outcomes of stroke patients in Nepal: a systematic review and meta-analysis. BMC Neurol 2023; 23:337. [PMID: 37749496 PMCID: PMC10519080 DOI: 10.1186/s12883-023-03382-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Accepted: 09/11/2023] [Indexed: 09/27/2023] Open
Abstract
BACKGROUND With an increasing burden of stroke, it is essential to minimize the incidence of stroke and improve stroke care by emphasizing areas that bring out the maximum impact. The care situation remains unclear in the absence of a national stroke care registry and a lack of structured hospital-based data monitoring. We conducted this systematic review and meta-analysis to assess the status of stroke care in Nepal and identify areas that need dedicated improvement in stroke care. METHODS A systematic literature review was conducted to identify all studies on stroke epidemiology or stroke care published between 2000 and 2020 in Nepal. Data analysis was done with Statistical Package for Social Sciences (SPSS) and Comprehensive Meta-analysis (CMA-3). RESULTS We identified 2533 studies after database searching, and 55 were included in quantitative and narrative synthesis. All analyses were done in tertiary care settings in densely populated central parts of Nepal. Ischemic stroke was more frequent (70.87%) than hemorrhagic (26.79%), and the mean age of stroke patients was 62,9 years. Mortality occurred in 16.9% (13-21.7%), thrombolysis was performed in 2.39% of patients, and no studies described thrombectomy or stroke unit care. CONCLUSION The provision of stroke care in Nepal needs to catch up to international standards, and our systematic review demonstrated the need to improve access to quality stroke care. Dedicated studies on establishing stroke care units, prevention, rehabilitation, and studies on lower levels of care or remote regions are required.
Collapse
Affiliation(s)
- Raju Paudel
- Grande International Hospital, Kathmandu, Nepal.
| | | | | | | | - Ayush Adhikari
- Tribhuvan Univerisity Teaching Hospital, Kathmandu, Nepal
| | | | | | - Avinash Chandra
- Annapurna Neurological Institute and Allied Sciences, Kathmandu, Nepal
| | - Ghanashyam Kharel
- National Institute of Neurological and Allied Sciences, Kathmandu, Nepal
| | | | | | | | - Subi Acharya
- Patan Academy of Health Sciences, Lalitpur, Nepal
| | | | - Pinky Jha
- Nepalese Army Institute of Health Sciences, Kathmandu, Nepal
| | | | | |
Collapse
|
75
|
Siahaan AMP, Indharty S, Tandean S, Tommy T, Loe ML, Nainggolan BWM, Pangestu D, Susanto M. Middle meningeal artery embolization and pediatric chronic subdural hematoma: a systematic review of the literature. Neurosurg Rev 2023; 46:239. [PMID: 37697174 DOI: 10.1007/s10143-023-02130-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 08/24/2023] [Accepted: 08/25/2023] [Indexed: 09/13/2023]
Abstract
Chronic subdural hematoma (CSDH) is a disease commonly found in the elderly and not a typical finding in pediatric population. History of shunt surgery, child abuse, and blood disorder are some of the common causes of pediatric CSDH (pCSDH). There is growing evidence about the role of middle meningeal artery embolization (MMAE) to manage CSDH in the elderly population with a high risk of rebleeding. However, the evidence in the pediatric population is still sparse. A systematic literature search was conducted on PubMed, Scopus, and Web of Science database from January, 2023, to March, 2023. Search strings were generated based on the combination of modified search terms, such as CSDH, MMA embolization, and child. Risk of bias was assessed using the Cochrane Risk of Bias in Nonrandomized Study for Intervention. Nine articles were included in this review. The success rate of MMA embolization in pediatric CSDH was 88.8%. Histories of ventriculoperitoneal shunt, blood coagulation disorder, and trauma were the causes of CSDH. Time to achieve success was varied from 2 to 9 months. No study with low risk of bias was found. This systematic review found no high-quality evidence regarding the role of MMA embolization in the management of pCSDH. However, due to its high success rate, MMAE could be a promising approach to treat pCSDH.
Collapse
Affiliation(s)
| | - Suzy Indharty
- Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| | - Steven Tandean
- Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| | - Thomas Tommy
- Department of Neurosurgery, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia
| | | | | | - Dimas Pangestu
- Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| | - Martin Susanto
- Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| |
Collapse
|
76
|
Ali A, Bastianon Santiago R, Isidor J, Mandel M, Adada M, Obrzut M, Adada B, Borghei-Razavi H. Debilitating trigeminal neuralgia secondary to idiopathic intracranial hypertension. Heliyon 2023; 9:e19756. [PMID: 37809543 PMCID: PMC10559059 DOI: 10.1016/j.heliyon.2023.e19756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Revised: 07/21/2023] [Accepted: 08/31/2023] [Indexed: 10/10/2023] Open
Abstract
Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure with unknown etiology. The most common neurological manifestations are headache and visual loss. Often, other cranial nerve impairments are also found, most commonly in the VI nerve. Trigeminal neuralgia (TN) is a debilitating condition that is most frequently caused by neurovascular pathology, but TN secondary to IIH is a rare and poorly described topic. Possible explanations of TN in these patients include the distortion of the local anatomy at CN entry zones and fluid displacement causing distortion of the Meckel's cave. In the case below we describe the clinical course of an obese female patient with TN-like pain who underwent a ventriculoperitoneal shunt to treat IIH and experienced complete resolution of both conditions.
Collapse
Affiliation(s)
- Assad Ali
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | | | - Julio Isidor
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | - Mauricio Mandel
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | - Mohamad Adada
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | - Michal Obrzut
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | - Badih Adada
- Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL, United States
| | | |
Collapse
|
77
|
Kharel S, Shrestha S, Pant SR, Acharya S, Sharma A, Baniya S, Bhandari SS. High-Altitude Exposure and Cerebral Venous Thrombosis: An Updated Systematic Review. High Alt Med Biol 2023; 24:167-174. [PMID: 37615608 DOI: 10.1089/ham.2022.0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/25/2023] Open
Abstract
Kharel, Sanjeev, Suraj Shrestha, Samriddha Raj Pant, Suman Acharya, Amit Sharma, Santosh Baniya, and Sanjeeb S. Bhandari. High-altitude exposure and cerebral venous thrombosis: an updated systematic review. High Alt Med Biol. 24:167-174, 2023. Background: High altitude (HA) may increase the risk of cerebral venous thrombosis (CVT). Differentiating it from other HA illnesses is crucial for prompt treatment and better outcomes. We aimed to summarize the clinical data, etiology, and risk factors of this poorly understood entity at an HA. Materials and Methods: A systematic literature search of various databases, including PubMed, Embase, and Google Scholar, was done using relevant keywords; cerebral venous thrombosis; HA, up to May 1, 2022. Results: A total of nine studies, including 75 cases of CVT at HA (3,000-8,848 m), with 66 males and 9 females, were included in this review. Headache and seizure were the most common clinical presentations. Smoking, drinking habits, and the use of oral contraceptive pills (OCP) were the most common risk factors for the development of CVT. Similarly, various underlying hypercoagulable states were also present among cases of CVT associated with HA exposure. Conclusion: Our review concludes that HA exposure can predispose individuals with risk factors such as preexisting hypercoagulable states, smoking, drinking habits, and use of OCP to an increased risk of CVT.
Collapse
Affiliation(s)
- Sanjeev Kharel
- Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
| | - Suraj Shrestha
- Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
- Mountain Medicine Society of Nepal, Kathmandu, Nepal
| | - Samriddha Raj Pant
- Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
- Mountain Medicine Society of Nepal, Kathmandu, Nepal
| | - Suman Acharya
- Mountain Medicine Society of Nepal, Kathmandu, Nepal
- Department of Internal Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
| | - Amit Sharma
- Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
| | | | - Sanjeeb S Bhandari
- Mountain Medicine Society of Nepal, Kathmandu, Nepal
- Collaboration for Emergency Care, Kathmandu, Nepal
| |
Collapse
|
78
|
Ma BJ, Ye HB, Meng GQ, Zhao W, Ye Z, Ji JF. Identification of key genes in spontaneous cerebral hemorrhage and prevention of disease damage: LASSO and SVM regression. Prev Med 2023; 174:107633. [PMID: 37473923 DOI: 10.1016/j.ypmed.2023.107633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 06/25/2023] [Accepted: 07/17/2023] [Indexed: 07/22/2023]
Abstract
Prevention is more important than treatment, and the incidence of intracerebral hemorrhage can be effectively reduced by intervening on the risk factors of intracerebral hemorrhage. By studying the risk factors of spontaneous intracerebral hemorrhage, we can identify the risk factors to achieve the target of treatment and prevention. Through the use of the Least Absolute Shrinkage and Selection Operator (LASSO) and the Support Vector Machine (SVM), the two essential SICH-related genes, NUAK1 and ERO1L, were eliminated from consideration. A Venn analysis was performed, and based on the two important modules, it found that SICH was related with four critical genes: VCM1, CRNDE, COL6A2, and HSPB6. One gene (NUAK1) was dramatically downregulated in the illness group compared to the control group, whereas three essential genes (ERO1L, VCAM1, and COL6A2) were significantly upregulated in the disease group. In the end, the genes ERO1L, VCAM1, COL6A2, and NUAK1 were shown to be the most important ones for SICH. It is anticipated that these genes will become novel biomarkers as well as targets for the development of new pharmacotherapies for SICH.
Collapse
Affiliation(s)
- Bao-Jun Ma
- Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China
| | - Han-Bin Ye
- Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China
| | - Gao-Qiang Meng
- Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China
| | - Wei Zhao
- Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China
| | - Zi Ye
- Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China.
| | - Jian-Feng Ji
- Department of Burn and Plastic, The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital, No. 6 Haier Lane North Road, Nantong 226001, China.
| |
Collapse
|
79
|
Orscelik A, Senol YC, Bilgin C, Kobeissi H, Arul S, Cloft H, Lanzino G, Kallmes DF, Brinjikji W. Middle meningeal artery embolization without surgical evacuation for chronic subdural hematoma: a single-center experience of 209 cases. Front Neurol 2023; 14:1222131. [PMID: 37719752 PMCID: PMC10501738 DOI: 10.3389/fneur.2023.1222131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Accepted: 08/03/2023] [Indexed: 09/19/2023] Open
Abstract
Background Middle meningeal artery (MMA) embolization is a minimally invasive treatment option for new and recurrent chronic subdural hematomas (cSDH). Objective To examine the safety and efficacy profile of MMA embolization without surgical evacuation for cSDH patients. Methods A single-center retrospective study of patients with cSDHs treated by MMA embolization was undertaken. Patient demographics, hematoma characteristics, procedural details, and clinical and radiological outcomes were collected. The primary outcome was the need for retreatment, and the secondary outcomes were at least a 50% reduction in the maximum width of cSDH on the last CT imaging, complications, and an improvement in the modified Rankin scale (mRS) score. All results were presented as descriptive statistics. Results A total of 209 MMA embolizations were successfully performed on 144 patients. Polyvinyl alcohol particles were the primary embolization agent in all procedures. Of the total of 206 cSDH, the median maximum width at pre-intervention and last follow-up were 12 and 3 mm, respectively, and the median reduction percentage was 77.5%, with a >50% improvement observed in 72.8% at the last follow-up imaging. A total of 13.8% of patients needed retreatment for recurrent, refractory, or symptomatic hematomas after embolization. The mRS score improved in 71 (49.3%) patients. Of 144 patients, 4 (2.8%) experienced complications related to the procedure, and 12 (8.4%) died during follow-up due to causes unrelated to the MMA embolization procedures. Conclusion This study supports the fact that MMA embolization without surgical evacuation is a safe and effective minimally invasive option for the treatment of cSDHs.
Collapse
Affiliation(s)
- Atakan Orscelik
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Yigit Can Senol
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States
| | - Cem Bilgin
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Hassan Kobeissi
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Santhosh Arul
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Harry Cloft
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Giuseppe Lanzino
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States
| | - David F. Kallmes
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Waleed Brinjikji
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States
| |
Collapse
|
80
|
Nakagawa I, Kotsugi M, Yokoyama S, Maeoka R, Tamura K, Takeshima Y, Matsuda R, Yamada S, Nishimura F, Park YS, Nakase H. Extensive Roles and Technical Advances of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma. Neurol Med Chir (Tokyo) 2023; 63:327-333. [PMID: 37286481 PMCID: PMC10482489 DOI: 10.2176/jns-nmc.2023-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 04/03/2023] [Indexed: 06/09/2023] Open
Abstract
Chronic subdural hematoma (CSDH) is a common pathology that typically affects the elderly in Japan, an aging society. Burr-hole irrigation is the standard treatment, but middle meningeal artery (MMA) embolization is a minimally invasive alternative. MMA embolization for CSDH has frequently been reported in recent years, and many technical innovations to improve clinical outcomes have been described. Embolic materials reaching more distally are found to avoid recurrences after MMA embolization. As a result, various studies have described the superiority of embolizing the anterior and posterior branches of the MMA, the advantages of embolic materials reaching beyond the midline, and a high degree of distal penetration using a "sugar rush technique" in which 5% soluble glucose is injected through an intermediate catheter during MMA embolization. Radiographically, reports have described the importance of a "bright falx" sign obtained by infiltrating embolic material beyond the midline and post-embolization enhancement of the dura, capsular membrane, septations, and subdural hematoma fluid as indicators of the spread of embolic materials. This review provides an overview of the current status and future challenges in MMA embolization for CSDH, focusing on technical aspects to improve clinical outcomes.
Collapse
|
81
|
Sioutas GS, Mannam SS, Corral Tarbay A, Nia AM, Salem MM, Vivanco-Suarez J, Burkhardt JK, Jankowitz BT, Srinivasan VM. Dexamethasone and Statins in Patients Undergoing Primary Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Propensity-Matched Study in the TriNetX Research Network. World Neurosurg 2023; 176:e83-e90. [PMID: 37164211 DOI: 10.1016/j.wneu.2023.04.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/28/2023] [Accepted: 04/29/2023] [Indexed: 05/12/2023]
Abstract
OBJECTIVE Middle meningeal artery embolization (MMAE) is an effective minimally invasive option for chronic subdural hematoma (cSDH). Dexamethasone and statins have been reported to improve the resolution of cSDH and reduce its recurrence. However, only 1 study has investigated the role of statins in patients treated with MMAE, and there is no such study on dexamethasone. Thus, we used the TriNetX research network to determine whether adding dexamethasone or statin along with primary MMAE is associated with a benefit in outcomes. METHODS We queried all primary MMAE cases for cSDH between January 1st, 2012, and July 1st, 2022, in the TriNetX research network. We included patients greater than or equal to 18 years old and separated them regarding statin and dexamethasone use around the time of MMAE. Outcomes were evaluated within 6 months and 3 years after MMAE, and analyses were performed before and after propensity score matching. RESULTS The study included 372 patients with chronic subdural hematoma who underwent MMAE and were on dexamethasone, 339 not on dexamethasone, 391 on statins, and 278 not on statins. After propensity score matching, the dexamethasone cohorts included 250 patients each and only headache remained more prevalent in the dexamethasone cohort at both 6 months (21.2% vs. 10.0%, P = 0.001) and 3 years (23.6% vs. 12.4%, P = 0.001). After propensity score matching, the statin cohorts included 150 patients each and no differences in outcomes were found at both 6 months and 3 months after MMAE. CONCLUSIONS Patients treated with primary MMAE and were on dexamethasone or statins had no differences in mortality and functional/provider dependence compared to those who were not on dexamethasone or statins. Patients on dexamethasone had a higher prevalence of headaches.
Collapse
Affiliation(s)
- Georgios S Sioutas
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Sneha Sai Mannam
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Antonio Corral Tarbay
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Anna M Nia
- Department of Neurological Surgery, Montefiore/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Mohamed M Salem
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Juan Vivanco-Suarez
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Jan-Karl Burkhardt
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Brian T Jankowitz
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA
| | - Visish M Srinivasan
- Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
82
|
Rahman RK, Majmundar N, San A, Sanmugananthan P, Berke C, Lang SS, Tayebi Meybodi A, Gajjar AA, Liu JK. Surgical Outcomes of Awake Craniotomy for Treatment of Arteriovenous Malformations in Eloquent Cortex: A Systematic Review. World Neurosurg 2023; 175:17-30. [PMID: 37004885 DOI: 10.1016/j.wneu.2023.03.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 03/24/2023] [Accepted: 03/25/2023] [Indexed: 04/01/2023]
Abstract
OBJECTIVE Arteriovenous malformations (AVMs) located in eloquent brain regions are historically associated with a poor prognosis. Awake craniotomy (AC) with the adjunct of brain mapping has the potential of identifying non-eloquent gyri to maximize resection, thereby theoretically decreasing the risk of neurologic deficits. With limited evidence regarding the efficacy of AC in treatment of eloquent AVMs, this review aims to investigate its surgical outcomes. METHODS A systematic search in the PubMed database was performed to identify all relevant studies up to February 2022. RESULTS A total of 13 studies were extracted for quantitative analysis, yielding a total of 46 patients. The mean age was 34.1 years, and most patients were female (54.8%). Seizures were the most frequently reported presenting symptom (41%, 19 of 46 cases). Spetzler-Martin Grade III was the most prevalent (45.9%, 17 cases) with a mean nidus size of 32.6 mm. Seventy-four percent of AVMs were located on the left side, with the frontal lobe being the most common location (30%, 14 of 46 cases). The most common eloquent regions were language (47.8%, 22 of 46 cases), motor (17.4%, 8 of 46 cases), and language + motor cortices (13.1%, 6 of 46 cases). Complete resection of AVM was achieved in 41 patients (89%). Intraoperative complications occurred in 14 of 46 cases (30.4%) with transient postoperative neurologic deficits in 14 patients (30.4%). CONCLUSIONS AC may enable precise microsurgical excision of eloquent AVMs with preservation of critical brain functions. Risk factors for poor outcomes include eloquent AVMs located in the language + motor regions and the occurrence of intraoperative complications such as seizures/hemorrhage.
Collapse
Affiliation(s)
- Raphia K Rahman
- Rowan University School of Osteopathic Medicine, Stratford, New Jersey, USA; Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - Neil Majmundar
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Ali San
- Kansas City University College of Osteopathic Medicine, Kansas City, Missouri, USA
| | | | - Chandler Berke
- Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Shih-Shan Lang
- Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ali Tayebi Meybodi
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Avi A Gajjar
- Department of Chemistry, Union College, Schenectady, New York, USA; Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - James K Liu
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
| |
Collapse
|
83
|
Uchida M, Tanikawa M, Nishikawa Y, Yamanaka T, Ueki T, Mase M. Endoscope-Controlled High Frontal Approach for Dural Arteriovenous Fistula in Anterior Cranial Fossa. World Neurosurg 2023; 175:e421-e427. [PMID: 37019304 DOI: 10.1016/j.wneu.2023.03.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/26/2023] [Accepted: 03/27/2023] [Indexed: 04/05/2023]
Abstract
BACKGROUND Currently, surgical obliterations are a mainstay for treating dural arteriovenous fistula (DAVF) in the anterior cranial fossa (ACF), which has high risks of hemorrhage and functional disorder. By introducing an endoscope into a high frontal approach and utilizing its advantages, we attempted to establish it as a new surgical procedure that eliminates the drawbacks of various approaches that have been used to date. METHODS By using 30 clinical datasets of venous-phase head computed tomography angiogram, measurements and comparisons on a 3-dimensional workstation were performed to identify the appropriate positioning of keyhole craniotomy for endoscope-controlled high frontal approach (EHFA). Based on these data, a cadaver-based surgery was simulated to verify the feasibility of EHFA and develop an efficient procedure. RESULTS In EHFA, though raising the position of the keyhole craniotomy made the operative field deeper, significant advantages were obtained in the angle between the operative axis and the medial-anterior cranial base and the amount of bone removal required at the anterior edge of craniotomy. Minimally invasive EHFA, performed through a keyhole craniotomy without opening the frontal sinus, proved to be feasible on 10 sides of 5 cadaver heads. Moreover, 3 patients with DAVF in ACF were successfully treated by clipping the fistula via EHFA. CONCLUSIONS EHFA, which provided a direct corridor to the medial ACF at the level of the foramen cecum and crista galli and the minimum necessary operative field, was found to be a suitable procedure for clipping the fistula of DAVF in ACF.
Collapse
Affiliation(s)
- Mitsuru Uchida
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Motoki Tanikawa
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
| | - Yusuke Nishikawa
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Tomoyasu Yamanaka
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Takatoshi Ueki
- Department of Integrative Anatomy, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Mitsuhito Mase
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| |
Collapse
|
84
|
Rodriguez B, Morgan I, Young T, Vlastos J, Williams T, Hrabarchuk EI, Tepper J, Baker T, Kellner CP, Bederson J, Rapoport BI. Surgical techniques for evacuation of chronic subdural hematoma: a mini-review. Front Neurol 2023; 14:1086645. [PMID: 37456631 PMCID: PMC10338715 DOI: 10.3389/fneur.2023.1086645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 05/30/2023] [Indexed: 07/18/2023] Open
Abstract
Chronic subdural hematoma is one of the most common neurosurgical pathologies with over 160,000 cases in the United States and Europe each year. The current standard of care involves surgically evacuating the hematoma through a cranial opening, however, varied patient risk profiles, a significant recurrence rate, and increasing financial burden have sparked innovation in the field. This mini-review provides a brief overview of currently used evacuation techniques, including emerging adjuncts such as endoscopic assistance and middle meningeal artery embolization. This review synthesizes the body of available evidence on efficacy and risk profiles for each critical aspect of surgical technique in cSDH evacuation and provides insight into trends in the field and promising new technologies.
Collapse
Affiliation(s)
- Benjamin Rodriguez
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Isabella Morgan
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Tirone Young
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Joseph Vlastos
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Tyree Williams
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Rensselaer Polytechnic Institute, Troy, NY, United States
| | - Eugene I. Hrabarchuk
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Jaden Tepper
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Turner Baker
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Christopher P. Kellner
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Joshua Bederson
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Benjamin I. Rapoport
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| |
Collapse
|
85
|
Martinez-Gutierrez JC, D'Amato SA, Zeineddine HA, Nahhas MI, Kole MJ, Kim HW, Kim Y, Dawes BH, Chen PR, Blackburn SL, Sheth SA, Spiegel G, Chen CJ, Mahapatra A, Kitagawa RS, Dannenbaum MJ. Middle meningeal artery embolization of septated chronic subdural hematomas. Interv Neuroradiol 2023:15910199231184521. [PMID: 37529885 DOI: 10.1177/15910199231184521] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023] Open
Abstract
INTRODUCTION Middle meningeal artery embolization (MMAE) has emerged as a promising new treatment for patients with chronic subdural hematomas (cSDH). Its efficacy, however, upon the subtype with a high rate of recurrence-septated cSDH-remains undetermined. METHODS From our prospective registry of patients with cSDH treated with MMAE, we classified patients based on the presence or absence of septations. The primary outcome was the rate of recurrence of cSDH. Secondary outcomes included a reduction in cSDH thickness, midline shift, and rate of reoperation. RESULTS Among 80 patients with 99 cSDHs, the median age was 68 years (IQR 59-77) with 20% females. Twenty-eight cSDHs (35%) had septations identified on imaging. Surgical evacuation with burr holes was performed in 45% and craniotomy in 18.8%. Baseline characteristics between no-septations (no-SEP) and septations (SEP) groups were similar except for median age (SEP vs no-SEP, 72.5 vs. 65.5, p = 0.016). The recurrence rate was lower in the SEP group (SEP vs. no-SEP, 3 vs. 16.7%, p = 0.017) with higher odds of response from MMAE for septated lesions even when controlling for evacuation strategy and antithrombotic use (OR = 0.06, CI [0.006-0.536], p = 0.012). MMAE resulted in higher mean absolute thickness reduction (SEP vs. no-SEP, -8.2 vs. -4.8 mm, p = 0.016) with a similar midline shift change. The rate of reoperation did not differ (6.2 vs. 3.1%, p = 0.65). CONCLUSION MMAE appears to be equal to potentially more effective in preventing the recurrence of cSDH in septated lesions. These findings may aid in patient selection.
Collapse
Affiliation(s)
| | - Salvatore A D'Amato
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Hussein A Zeineddine
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Michael I Nahhas
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Matthew J Kole
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Hyun Woo Kim
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Youngran Kim
- Division of Management, Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Bryden H Dawes
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Peng Roc Chen
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Spiros L Blackburn
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Sunil A Sheth
- Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Gary Spiegel
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Ching-Jen Chen
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Ashutosh Mahapatra
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
- Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Ryan S Kitagawa
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Mark J Dannenbaum
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA
| |
Collapse
|
86
|
Prasetyo BT, Kurniawan RG, Rilianto B, Windiani PR, Gotama KT, Salam S, Sari IM, Musridharta E, Arham A, Kusdiansah M, Kiemas LS, Bustami M. Clinical prediction score for prolonged length of hospital stay in aneurysmal subarachnoid hemorrhage. BMC Neurol 2023; 23:232. [PMID: 37328746 DOI: 10.1186/s12883-023-03279-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 06/06/2023] [Indexed: 06/18/2023] Open
Abstract
BACKGROUND Length of stay (LOS) is an important indicator of the optimization of health services and hospital financing efficiency in aneurysmal subarachnoid hemorrhage (aSAH) patients. The purpose of this study was to develop a scoring model to predict the LOS of patients with aSAH. METHOD A clinical scoring was developed based on retrospectively collected data from the cerebral aneurysm registry of the National Brain Center Hospital, Jakarta, from January 2019 to June 2022. Multivariate logistic regression was used to determine the odds ratio for risk-adjusted prolonged LOS. LOS predictors were obtained based on the regression coefficients and converted into a point score model. RESULTS Of the 209 aSAH patients observed, 117 patients had prolonged LOS (> 14 days of hospital stay). A clinical score was developed with a range of 0-7 points. Four variables were chosen as predictors of prolonged LOS: the presence of high-grade aSAH (1 point), aneurysm treatment (endovascular coiling: 1 point; surgical clipping: 2 points), cardiovascular comorbidities (1 point), and hospital-acquired pneumonia (3 points). The score showed good discrimination with an area under the receiving operating characteristics curve (AUC) of 0.8183 (SE 0.0278) and a p-value for the Hosmer-Lemeshow (HL) goodness-of-fit of 0.9322. CONCLUSION This simple clinical score reliably predicted prolonged LOS in aneurysmal subarachnoid hemorrhage cases and may aid clinicians in improving patient outcomes and decreasing healthcare costs.
Collapse
Affiliation(s)
- Bambang Tri Prasetyo
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Ricky Gusanto Kurniawan
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
| | - Beny Rilianto
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia.
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
| | - Pratiwi Raissa Windiani
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia
| | - Kelvin Theandro Gotama
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia
| | - Sardiana Salam
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Neurointensive Care, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Ita Muharram Sari
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Neurointensive Care, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Eka Musridharta
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Neurointensive Care, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Abrar Arham
- Neurointervention Division, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Letjen Mt. Haryono Street, No. Kav. 11, East Jakarta, Indonesia
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Department of Neurosurgery, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Muhammad Kusdiansah
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Department of Neurosurgery, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Lyna Soertidewi Kiemas
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Neuroscience Unit, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| | - Mursyid Bustami
- Faculty of Medicine, Airlangga University, Surabaya, Indonesia
- Neurointensive Care, National Brain Center Hospital Prof. Dr. dr. Mahar Mardjono, Jakarta, Indonesia
| |
Collapse
|
87
|
Kaur G, Narayanan K, Schroeder K, Al Shakarchi F, Hakoun AM. An Approach for Cognitive Evaluation and Management of Grade 5 Arteriovenous Malformation-Associated Thalamic Dementia: A Case Report and Literature Review. Cureus 2023; 15:e39913. [PMID: 37404406 PMCID: PMC10317249 DOI: 10.7759/cureus.39913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2023] [Indexed: 07/06/2023] Open
Abstract
The clinical approach to managing high-grade arteriovenous malformations (AVMs) has been challenging due to its various presentations, surgical risk of complications, and impact on patients' quality of life. We report a case of a 57-year-old female who experienced recurrent seizures and progressive cognitive decline secondary to a grade 5 cerebellar AVM. We reviewed the patient's presentation and clinical course. We also searched the literature for studies, reviews, and case reports involving the management of high-grade AVMs. We outline our recommendations on how to approach these cases after a review of the currently available treatment options.
Collapse
Affiliation(s)
- Gunjanpreet Kaur
- Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
| | - Karthik Narayanan
- Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
| | - Kyle Schroeder
- Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
| | - Firas Al Shakarchi
- Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
| | - Abdullah M Hakoun
- Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
| |
Collapse
|
88
|
Khorasanizadeh M, Shutran M, Garcia A, Enriquez-Marulanda A, Moore J, Ogilvy CS, Thomas AJ. Middle meningeal artery embolization for treatment of chronic subdural hematomas: does selection of embolized branches affect outcomes? J Neurosurg 2023; 138:1494-1502. [PMID: 36681986 DOI: 10.3171/2022.9.jns221663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Accepted: 09/26/2022] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Middle meningeal artery (MMA) embolization (MMAE) is a new therapeutic modality for chronic subdural hematoma (cSDH). There is limited evidence comparing various MMAE procedural techniques, resulting in significant variations in technique and procedural planning. The objective of this study was to compare outcomes of MMAE by the number and location of MMA branches that were embolized. METHODS A single-center retrospective study of patients with cSDH treated by MMAE was conducted. Clinical outcomes, need for re-intervention, and changes in hematoma size were compared between different MMAE techniques. RESULTS Ninety-four cSDHs in 78 patients were included. Embolization of the proximal trunk only, distal branches only, or proximal trunk plus distal branches resulted in similar rates of need for rescue surgery (7.4%, 13.0%, and 6.8%, respectively; p = 0.66) and rates of reducing the volume of the hematoma by at least 50% (74.1%, 80.0%, and 77.5%, respectively; p = 0.88). Embolization of only one branch had similar outcomes to embolization of more than one branch, as rescue surgery rates were 9.3% and 7.8% (p = 0.80), and rates ≥ 50% volume reduction were 75.6% and 78.3% (p = 0.76), respectively. Selective embolization of the dominant MMA branch was not associated with significantly different outcomes. CONCLUSIONS Outcomes of distal, proximal, or combined proximal and distal MMAE in cSDH are not significantly different. Embolization of more than one branch is not associated with improved treatment efficacy. Arguably, targeting any location in the MMA provides sufficient flow restriction to enable spontaneous hematoma resolution. Accordingly, a technical planning algorithm for cSDH MMAE is suggested.
Collapse
Affiliation(s)
- MirHojjat Khorasanizadeh
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Max Shutran
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Alfonso Garcia
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Alejandro Enriquez-Marulanda
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Justin Moore
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Christopher S Ogilvy
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Ajith J Thomas
- 2Department of Neurological Surgery, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey
| |
Collapse
|
89
|
Guo Y, Yu J. Treatment of filum terminale pial arteriovenous fistulas in the sacral region: A case report and systematic review. Neuroradiol J 2023; 36:251-258. [PMID: 36086815 PMCID: PMC10268093 DOI: 10.1177/19714009221126017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Spinal filum terminale pial arteriovenous fistulas (FT PAVFs) are uncommon. Most FT PAVFs are located in the lumbar region; far fewer are located in the sacral region. Due to the rarity of sacral FT PAVFs, the precise surgical dissection and removal of these lesions are challenging. Here, we report an FT PAVF in the sacral region. The patient was a 45-year-old male who suffered from progressive weakness and numbness of the bilateral lower limbs; his symptoms gradually worsened. Digital subtraction angiography (DSA) showed an AVF at the sacral canal at the S3-4 level. Microsurgical treatment with intraoperative DSA was performed, and the FT PAVF was resected. After the operation, the patient gradually recovered. Follow-up magnetic resonance imaging revealed a recession in the dilation of the spinal cord venous plexuses. A literature review was also performed, and a total of 14 FT PAVFs of the sacral region were identified. The patients identified in the literature review had an average age of 58.9 ± 12.9 years, and 92.9% of the patients were male. Spinal cord edema was present in 85.7% of the FT PAVF patients. Regarding treatment, 64.3% of the FT PAVF patients underwent microsurgical resection, 28.6% patients underwent endovascular treatment, and 7.1% patients underwent a hybrid operation; good outcomes were achieved with all three methods. Therefore, FT PAVF of the sacral region is a unique lesion whose angioarchitecture needs to be identified carefully; prompt treatment is necessary, and microsurgery can yield good outcomes.
Collapse
Affiliation(s)
- Yunbao Guo
- Department of Neurosurgery, the First Hospital of Jilin
University, Changchun, China
| | - Jinlu Yu
- Department of Neurosurgery, the First Hospital of Jilin
University, Changchun, China
| |
Collapse
|
90
|
Sattari SA, Yang W, Shahbandi A, Feghali J, Lee RP, Xu R, Jackson C, Gonzalez LF, Tamargo RJ, Huang J, Caplan JM. Middle Meningeal Artery Embolization Versus Conventional Management for Patients With Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis. Neurosurgery 2023; 92:1142-1154. [PMID: 36929762 DOI: 10.1227/neu.0000000000002365] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 11/15/2022] [Indexed: 03/18/2023] Open
Abstract
BACKGROUND The results from studies that compare middle meningeal artery (MMA) embolization vs conventional management for patients with chronic subdural hematoma are varied. OBJECTIVE To conduct a systematic review and meta-analysis on studies that compared MMA embolization vs conventional management. METHODS Medline, PubMed, and Embase databases were searched. Primary outcomes were treatment failure and surgical rescue; secondary outcomes were complications, follow-up modified Rankin scale > 2, mortality, complete hematoma resolution, and length of hospital stay (day). The certainty of the evidence was determined using the GRADE approach. RESULTS Nine studies yielding 1523 patients were enrolled, of which 337 (22.2%) and 1186 (77.8%) patients received MMA embolization and conventional management, respectively. MMA embolization was superior to conventional management for treatment failure (relative risk [RR] = 0.34 [0.14-0.82], P = .02), surgical rescue (RR = 0.33 [0.14-0.77], P = .01), and complete hematoma resolution (RR = 2.01 [1.10-3.68], P = .02). There was no difference between the 2 groups for complications (RR = 0.93 [0.63-1.37], P = .72), follow-up modified Rankin scale >2 (RR = 0.78 [0.449-1.25], P = .31), mortality (RR = 1.05 [0.51-2.14], P = .89), and length of hospital stay (mean difference = -0.57 [-2.55, 1.41], P = .57). For MMA embolization, the number needed to treat for treatment failure, surgical rescue, and complete hematoma resolution was 7, 9, and 3, respectively. The certainty of the evidence was moderate to high for primary outcomes and low to moderate for secondary outcomes. CONCLUSION MMA embolization decreases treatment failure and the need for surgical rescue without furthering the risk of morbidity and mortality. The authors recommend considering MMA embolization in the chronic subdural hematoma management.
Collapse
Affiliation(s)
- Shahab Aldin Sattari
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Wuyang Yang
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ataollah Shahbandi
- Tehran School of Medicine, Tehran University of Medical Science, Tehran, Iran
| | - James Feghali
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ryan P Lee
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Risheng Xu
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Christopher Jackson
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - L Fernando Gonzalez
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Rafael J Tamargo
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Judy Huang
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Justin M Caplan
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
91
|
Liebert A, Voit-Höhne H, Ritter L, Eibl T, Hammer A, Städt M, Eff F, Holtmannspötter M, Steiner HH. Embolization of the middle meningeal artery vs. second surgery-treatment response and volume course of recurrent chronic subdural hematomas. Acta Neurochir (Wien) 2023:10.1007/s00701-023-05621-7. [PMID: 37247035 DOI: 10.1007/s00701-023-05621-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 05/05/2023] [Indexed: 05/30/2023]
Abstract
BACKGROUND Despite multiple studies on the embolization of the middle meningeal artery, there is limited data on the treatment response of recurrent chronic subdural hematomas (CSDH) to embolization and on the volume change. METHODS We retrospectively compared the treatment response and volume change of recurrent CSDHs in a conventional group (second surgery) with an embolization group (embolization as stand-alone treatment) during the time-period from August 2019 until June 2022. Different clinical and radiological factors were assessed. Treatment failure was defined as necessity of treatment for second recurrence. Hematoma volumes were determined in the initial CT scan before first surgery, after the first surgery, before retreatment as well as in an early (1 day-2 weeks) and in a late follow-up CT scan (2-8 weeks). RESULTS Fifty recurrent hematomas after initial surgery were treated either by second surgery (n = 27) or by embolization (n = 23). 8/27 (26,6%) surgically treated and 3/23 (13%) of the hematomas treated by embolization needed to be treated again. This leads to an efficacy in recurrent hematomas of 73,4% in surgically treated and of 87% in embolized hematomas (p = 0.189). In the conventional group, mean volume decreased significantly already in the first follow-up CT scan from 101.7 ml (SD 53.7) to 60.7 ml (SD 40.3) (p = 0.001) and dropped further in the later follow-up scan to 46.6 ml (SD 37.1) (p = 0.001). In the embolization group, the mean volume did decrease insignificantly from 75.1 ml (SD 27.3) to 68 ml (SD 31.4) in the first scan (p = 0.062). However, in the late scan significant volume reduction to 30.8 ml (SD 17.1) could be observed (p = 0.002). CONCLUSIONS Embolization of the middle meningeal artery is an effective treatment option for recurrent CSDH. Patients with mild symptoms who can tolerate slow volume reduction are suitable for embolization, whereas patients with severe symptoms should be reserved for surgery.
Collapse
Affiliation(s)
- Adrian Liebert
- Department of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
| | - Heinz Voit-Höhne
- Department of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Leonard Ritter
- Department of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Thomas Eibl
- Department of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Alexander Hammer
- Department of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
- Center for Spinal and Scoliosis Surgery, Malteser Waldkrankenhaus St. Marien, Erlangen, Bavaria, Germany
| | - Michael Städt
- Department of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Florian Eff
- Department of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Markus Holtmannspötter
- Department of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| | - Hans-Herbert Steiner
- Department of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany
| |
Collapse
|
92
|
Salem MM, Kuybu O, Nguyen Hoang A, Baig AA, Khorasanizadeh M, Baker C, Hunsaker JC, Mendez AA, Cortez G, Davies JM, Narayanan S, Cawley CM, Riina HA, Moore JM, Spiotta AM, Khalessi AA, Howard BM, Hanel R, Tanweer O, Levy EI, Grandhi R, Lang MJ, Siddiqui AH, Kan P, Ogilvy CS, Gross BA, Thomas AJ, Jankowitz BT, Burkhardt JK. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations. Radiology 2023; 307:e222045. [PMID: 37070990 PMCID: PMC10323293 DOI: 10.1148/radiol.222045] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 01/25/2023] [Accepted: 03/01/2023] [Indexed: 04/19/2023]
Abstract
Background Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose To identify predictors of MMAE treatment failure for CSDH. Materials and Methods In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P = .007) and an MMA diameter less than 1.5 mm (OR, 2.52; P = .027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P = .011). For radiographic failure, female sex (OR, 0.36; P = .001), concurrent surgical evacuation (OR, 0.43; P = .009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P = .044), midline shift (OR, 1.1; P = .02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P = .029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (<1.5 mm) being the only factor independently associated with both clinical and radiographic failures. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Chaudhary and Gemmete in this issue.
Collapse
Affiliation(s)
- Mohamed M. Salem
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Okkes Kuybu
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alex Nguyen Hoang
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ammad A. Baig
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Mirhojjat Khorasanizadeh
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Cordell Baker
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Joshua C. Hunsaker
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Aldo A. Mendez
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Gustavo Cortez
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Jason M. Davies
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Sandra Narayanan
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - C. Michael Cawley
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Howard A. Riina
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Justin M. Moore
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alejandro M. Spiotta
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alexander A. Khalessi
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Brian M. Howard
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ricardo Hanel
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Omar Tanweer
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Elad I. Levy
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ramesh Grandhi
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Michael J. Lang
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Adnan H. Siddiqui
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Peter Kan
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Christopher S. Ogilvy
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Bradley A. Gross
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ajith J. Thomas
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Brian T. Jankowitz
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Jan-Karl Burkhardt
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| |
Collapse
|
93
|
Saal-Zapata G, Murga-Villanueva A, Walker M, Ghodke B, Rodríguez-Varela R. Safety and radiologic clearance of chronic subdural hematoma after endovascular embolization using SQUID 18 in patients older than 80 years. J Neurosci Rural Pract 2023; 14:336-341. [PMID: 37181175 PMCID: PMC10174137 DOI: 10.25259/jnrp_30_2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 01/15/2023] [Indexed: 02/25/2023] Open
Abstract
The aim of the study was to evaluate radiographic clearance and clinical outcomes in patients over age 80 who undergo SQUID 18 embolization of the middle meningeal artery (MMA) for the management of chronic subdural hematoma (cSDH). From April 2020 to October 2021, data were obtained from patients with cSDH who underwent MMA embolization at our institution. Clinical and radiological data including pre-operative and last follow-up CT scans were analyzed. Six embolization procedures were performed in five patients using SQUID 18, a liquid embolic agent. The median age was 83 years, and three subjects were female. Two of the six cases were recurrent hematomas. MMA embolization was achieved in 100% of cases. The median diameter of the hematoma at admission was 20 mm and at last follow-up was 5.3 mm, demonstrating statistically significant radiographic clearance (P = 0.043). There were no intra or post-operative complications. Mortality was not noted during observation period. SQUID MMA embolization safely and significantly reduced the hematoma diameter and offers an alternative treatment in patients older than 80 years with cSDH.
Collapse
Affiliation(s)
- Giancarlo Saal-Zapata
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Annel Murga-Villanueva
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Melanie Walker
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Basavaraj Ghodke
- Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
| | - Rodolfo Rodríguez-Varela
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| |
Collapse
|
94
|
Salih M, Khorasanizadeh M, McMillan N, Gomez-Paz S, Thomas AJ, Ogilvy CS, Moore JM. Cost Comparison for Open Surgery versus Middle Meningeal Artery Embolization in Patients with Chronic Subdural Hematomas: A Propensity Score-Matched Analysis. World Neurosurg 2023; 172:e94-e99. [PMID: 36549437 DOI: 10.1016/j.wneu.2022.12.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Accepted: 12/09/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Chronic subdural hematoma (cSDH) can be treated with conventional surgery or middle meningeal artery embolization (MMAE). The cost profiles of open surgery versus MMAE have never been studied. Therefore, we sought to compare the costs of surgical and MMAE treatment of cSDH. METHODS Patients treated with open surgery (2006-2019) and MMAE (2018-2020) were identified from the institutional database. Propensity score matching analysis was used to assemble a balanced group of subjects. Detailed hospitalization costs in each group were collected and compared. RESULTS A total of 341 conventionally treated and 52 MMAE cases were identified. After propensity score matching, 33 patients were included in each group, for a total of 66 patients for analysis. Direct procedural cost was significantly greater in the MMAE group compared with the open surgery group ($38,255 ± $11,859 vs. $11,206 ± $7888; P < 0.001). Medication cost also was greater in the MMAE group ($6888 ± $6525 vs. $4291 ± $3547; P = 0.048). No significant difference was found in costs for intensive care unit care, pharmacy, therapy, laboratory values, and the emergency department. Imaging costs and other miscellaneous costs (e.g., wound care, preoperative, and postanesthesia care unit) were greater in the open surgery group (P < 0.05). Total hospitalization cost was not significantly different between the 2 groups ($60,598 ± 61,315 vs. $71,569 ± $37,813 for open surgery and MMAE respectively, P = 0.385). No significant differences in number of follow ups or total costs for follow up were found (P > 0.05). CONCLUSIONS Open surgery and MMAE offer an overall equivalent cost-profile for cSDH treatment when matching for potential cost confounders. Direct procedural costs are greater in MMAE; however, total hospitalization costs and follow up costs are not significantly different.
Collapse
Affiliation(s)
- Mira Salih
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - MirHojjat Khorasanizadeh
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Nadia McMillan
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Santiago Gomez-Paz
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Ajith J Thomas
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Christopher S Ogilvy
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Justin M Moore
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
| |
Collapse
|
95
|
Development and validation of a recurrent prediction model for patients with unilateral chronic subdural hematoma without hematoma volumetric analysis. Clin Neurol Neurosurg 2023; 227:107678. [PMID: 36933403 DOI: 10.1016/j.clineuro.2023.107678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 03/11/2023] [Accepted: 03/14/2023] [Indexed: 03/18/2023]
Abstract
OBJECTIVE Approximately 10 % of patients with chronic subdural hematoma (CSDH) undergo reoperation after initial surgery. This study aimed to develop a predictive model for the recurrence of unilateral CSDH at initial surgery without hematoma volumetric analysis. METHODS This single-center retrospective cohort study evaluated pre- and postoperative computed tomography (CT) images of patients with unilateral CSDH. The pre- and postoperative midline shift (MLS), residual hematoma thickness, and subdural cavity thickness (SCT) were measured. CT images were classified based on the internal architecture of the hematoma (homogenous, laminar, trabecular, separated, and gradation subtypes). RESULTS Total 231 patients with unilateral CSDH underwent burr hole craniostomy. After receiver operating characteristic analysis, preoperative MLS and postoperative SCT showed better areas under the curve (AUCs) (0.684 and 0.756, respectively). According to the CT classification of preoperative hematomas, the recurrence rate was significantly higher in the separated/gradation group (18/97, 18.6 %) than in the homogenous/laminar/trabecular group (10/134, 7.5 %). Four-point score was derived from the multivariate model using the preoperative MLS, postoperative SCT, and CT classification. The AUC of this model was 0.796, and the recurrence rates at 0-4 points were 1.7 %, 3.2 %, 13.3 %, 25.0 %, and 35.7 %, respectively. CONCLUSION Pre- and postoperative CT findings without hematoma volumetric analysis may predict CSDH recurrence.
Collapse
|
96
|
Lim JS, Lee J, Kang Y, Park HT, Kim DE, Cha JK, Park TH, Heo JH, Lee KB, Park JM, Oh MS, Kim EG, Chang DI, Heo SH, Park MS, Park H, Yi S, Lee YB, Park KY, Lee SJ, Kim JG, Lee J, Cho KH, Rha JH, Kim YI, Lee JH, Choi JC, Oh KM, Kwon JH, Kim C, Park JH, Jung KH, Sung SM, Chung JW, Lee YS, Kim HY, Cho HJ, Park JW, Moon WJ, Bae HJ. Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. Contemp Clin Trials 2023; 126:107108. [PMID: 36724841 DOI: 10.1016/j.cct.2023.107108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 01/23/2023] [Accepted: 01/25/2023] [Indexed: 01/30/2023]
Abstract
BACKGROUND Oxiracetam may have a modest effect on preventing cognitive decline. Exercise can also enhance cognitive function. This trial aims to investigate the effect of oxiracetam on post-stroke cognitive impairment and explore whether this effect is modified by exercise. Furthermore, the mechanisms that mediate this effect will be investigated through a neural network analysis. METHODS This is a multicenter, randomized, double-blind, placebo-controlled phase IV trial. Patients who complained of cognitive decline 3 months after stroke and had a high risk of cognitive decline were eligible. Patients were randomly assigned to receive either 800 mg of oxiracetam or placebo twice daily for 36 weeks. After randomization, a predetermined exercise protocol was provided to each participant, and the degree of physical activity was assessed using wrist actigraphy at 4, 12, 24, and 36 weeks. Resting-state functional MRI was obtained in baseline and 36-week follow-up. Co-primary endpoints are changes in the Mini-Mental State Examination and Clinical Dementia Rating-Sum of Boxes. Secondary endpoints include changes in the NINDS-CSN VCIHS-Neuropsychology Protocol, Euro QoL, patient's global assessment, and functional network connectivity. If there is a significant difference in physical activity between the two groups, the interaction effect between physical activity and the treatment group will be examined. A total of 500 patients were enrolled from February 2018, and the last patient's final follow-up was completed in September 2022. CONCLUSION This trial is meaningful not only to prove the efficacy of oxiracetam, but also evaluate whether exercise can modify the effects of medication and how cognitive function can be restored. Trial registrationhttp://cris.nih.go.kr (KCT0005137).
Collapse
Affiliation(s)
- Jae-Sung Lim
- Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Juneyoung Lee
- Department of Biostatistics, Korea University, Seoul, Republic of Korea
| | - Yeonwook Kang
- Department of Psychology, Hallym University, Chuncheon, Republic of Korea
| | - Hyun-Tae Park
- Department of Health Sciences, Graduate School, Dong-A University, Busan, Republic of Korea
| | - Dong-Eog Kim
- Department of Neurology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Ilsan, Republic of Korea
| | - Jae-Kwan Cha
- Department of Neurology, Dong-A University Hospital, Busan, Republic of Korea
| | - Tai Hwan Park
- Department of Neurology, Seoul Medical Center, Seoul, Republic of Korea
| | - Jae-Hyuk Heo
- Department of Neurology, Seoul Medical Center, Seoul, Republic of Korea
| | - Kyung Bok Lee
- Department of Neurology, Soonchunhyang University Hospital, Seoul, Republic of Korea
| | - Jong-Moo Park
- Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Republic of Korea
| | - Mi Sun Oh
- Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
| | - Eung-Gyu Kim
- Department of Neurology, Inje University Busan Paik Hospital, Inje University, Busan, Republic of Korea
| | - Dae-Il Chang
- Department of Neurology, Kyung Hee University Hospital, Seoul, Republic of Korea
| | - Sung Hyuk Heo
- Department of Neurology, Kyung Hee University Hospital, Seoul, Republic of Korea
| | - Man-Seok Park
- Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - HyunYoung Park
- Department of Neurology, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Republic of Korea
| | - SangHak Yi
- Department of Neurology, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Republic of Korea
| | - Yeong Bae Lee
- Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
| | - Kwang-Yeol Park
- Department of Neurology, Chung-Ang University Medical Center, Chung-Ang University College of Medicine, Republic of Korea
| | - Soo Joo Lee
- Department of Neurology, Daejeon Eulji Medical Center, Eulji University, School of Medicine, Daejeon, Republic of Korea
| | - Jae Guk Kim
- Department of Neurology, Daejeon Eulji Medical Center, Eulji University, School of Medicine, Daejeon, Republic of Korea
| | - Jun Lee
- Department of Neurology, Yeungnam University Hospital, Yeungnam University School of Medicine, Daegu, Republic of Korea
| | - Kyung-Hee Cho
- Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea
| | - Joung-Ho Rha
- Department of Neurology, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea
| | - Yeong-In Kim
- Department of Neurology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Republic of Korea
| | - Jun Hong Lee
- Department of Neurology, National Health Insurance Service Ilsan Hospital, Ilsan, Republic of Korea
| | - Jay Chol Choi
- Department of Neurology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Republic of Korea
| | - Kyung-Mi Oh
- Department of Neurology, Korea Univeristy Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
| | - Jee-Hyun Kwon
- Department of Neurology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Republic of Korea
| | - Chulho Kim
- Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea
| | - Jong-Ho Park
- Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea
| | - Keun-Hwa Jung
- Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Sang Min Sung
- Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, Republic of Korea
| | - Jong-Won Chung
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Yong-Seok Lee
- Department of Neurology, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Hahn Young Kim
- Department of Neurology, Konkuk University Hospital, Konkuk University, Seoul, Republic of Korea
| | - Hyun-Ji Cho
- Department of Neurology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea
| | - Jeong Wook Park
- Department of Neurology, Uijeongbu St. Mary's Hospital, Catholic University of Korea, Uijeongbu, Republic of Korea
| | - Won-Jin Moon
- Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea
| | - Hee-Joon Bae
- Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
| |
Collapse
|
97
|
Ku JC, Dmytriw AA, Essibayi MA, Banihashemi MA, Vranic JE, Ghozy S, Altschul D, Regenhardt RW, Stapleton CJ, Yang VXD, Patel AB. Embolic Agent Choice in Middle Meningeal Artery Embolization as Primary or Adjunct Treatment for Chronic Subdural Hematoma: A Systematic Review and Meta-analysis. AJNR Am J Neuroradiol 2023; 44:297-302. [PMID: 36797028 PMCID: PMC10187811 DOI: 10.3174/ajnr.a7796] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 01/24/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND Middle meningeal artery embolization is an emerging treatment option for chronic subdural hematomas. PURPOSE Our aim was to assess outcomes following middle meningeal artery embolization by different techniques, including in comparison with traditional surgical methods. DATA SOURCES We searched the literature databases from inception to March 2022. DATA SELECTION We selected studies reporting outcomes after middle meningeal artery embolization as a primary or adjunctive treatment for chronic subdural hematoma. DATA ANALYSIS We analyzed the risk of recurrence of chronic subdural hematoma, reoperation for recurrence or residual hematoma, complications, and radiologic and clinical outcomes using random effects modeling. Additional analyses were performed on the basis of whether middle meningeal artery embolization was used as the primary or adjunct treatment and by embolic agent type. DATA SYNTHESIS Twenty-two studies were included with 382 patients with middle meningeal artery embolization and 1373 surgical patients. The rate of subdural hematoma recurrence was 4.1%. Fifty (4.2%) patients underwent a reoperation for a recurrent or residual subdural hematoma. Thirty-six (2.6%) experienced postoperative complications. The rates of good radiologic and clinical outcomes were 83.1% and 73.3%, respectively. Middle meningeal artery embolization was significantly associated with decreased odds of subdural hematoma reoperation (OR = 0.48; 95% CI, 23.4-99.1; P = .047) compared with surgery. The lowest rates of subdural hematoma radiologic recurrence, reoperation, and complications were observed among patients receiving embolization with Onyx, whereas good overall clinical outcome occurred most commonly with combined polyvinyl alcohol and coils. LIMITATIONS A limitation was the retrospective design of studies included. CONCLUSIONS Middle meningeal artery embolization is safe and effective, either as a primary or adjunctive treatment. Treatment using Onyx seems to yield lower rates of recurrence, rescue operation, and complications whereas particles and coils produce good overall clinical outcomes.
Collapse
Affiliation(s)
- J C Ku
- From the Division of Neurosurgery (J.C.K.)
| | - A A Dmytriw
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- Neurointerventional Program (A.A.D., V.X.D.Y.), Department of Clinical Neurological Sciences & Medical Imaging, Schulich School of Medicine, Western University, London, Ontario, Canada
| | - M A Essibayi
- Departments of Radiology (M.A.E., S.G.), Mayo Clinic, Rochester, Minnesota
- Department of Neurosurgery (M.A.E., D.A.), Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York
| | - M A Banihashemi
- Department of Surgery and Institute of Medical Science (M.A.B.), University of Toronto, Toronto, Ontario, Canada
| | - J E Vranic
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - S Ghozy
- Departments of Radiology (M.A.E., S.G.), Mayo Clinic, Rochester, Minnesota
- Nuffield Department of Primary Care Health Sciences and Department for Continuing Education (EBHC program) (S.G.), Oxford University, Oxford, UK
| | - D Altschul
- Department of Neurosurgery (M.A.E., D.A.), Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York
| | - R W Regenhardt
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - C J Stapleton
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - V X D Yang
- Neurointerventional Program (A.A.D., V.X.D.Y.), Department of Clinical Neurological Sciences & Medical Imaging, Schulich School of Medicine, Western University, London, Ontario, Canada
| | - A B Patel
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
98
|
Clinical and prognostic characteristics of cerebral venous thrombosis at high altitude: a single-center retrospective study of Tibet. J Neurol 2023; 270:2688-2692. [PMID: 36754900 DOI: 10.1007/s00415-023-11597-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 01/26/2023] [Accepted: 01/29/2023] [Indexed: 02/10/2023]
Abstract
OBJECTIVE Data regarding diagnosis, management, and prognosis of patients with cerebral venous thrombosis (CVT) from high altitude are limited. The aim of the present study is to identify the clinical features, risk factors, and outcomes of cerebral venous thrombosis (CVT) in Tibet. METHODS We retrospectively included patients with a diagnosis of CVT consecutively admitted to Tibet Autonomous Region People's Hospital between July 2015, and September 2022. The risk factors, clinical and radiological presentations, treatment and outcomes were analyzed. RESULTS A total of 38 patients with CVT were included in this study. The median age was 31 years, and females accounted for 63.2%. Patients of Tibetan nationality accounted for 71.1% (n = 27) and the median altitude of residence in Tibet was 3800 m (3657, 4054). Headache was the most common symptom (92.1%). The most common risk factors of CVT were infection in the past 4 weeks (34.2%) and pregnancy or puerperium (23.7%). Lateral sinus (transverse and/or sigmoid sinus) (68.4%) and superior sagittal sinus (55.3%) were the most commonly involved. The D-dimer increased in 31 patients (81.6%). All three patients who died in hospital and during follow-up had risk factor of recent infection. Favorable outcome at follow-up with a median length of 454 days (189, 1059) was observed in 85.3% of patients. CONCLUSIONS CVT at high altitude is more common in young patients and women, with various clinical manifestations and risk factors. Recent infection is the most common risk factor and may increase the mortality of CVT at high altitude. The long-term prognosis of CVT at high altitude is favorable.
Collapse
|
99
|
Zheng Y, Wan KR. Letter to the Editor. Role of adjuvant medical therapy in chronic subdural hematoma. J Neurosurg 2023; 138:584-585. [PMID: 36152324 DOI: 10.3171/2022.7.jns221715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Yilong Zheng
- 1Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | | |
Collapse
|
100
|
Martinez-Gutierrez JC, Zeineddine HA, Nahhas MI, Kole MJ, Kim Y, Kim HW, D'Amato SA, Chen PR, Blackburn SL, Spiegel G, Sheth SA, Kitagawa RS, Dannenbaum MJ. Middle Meningeal Artery Embolization for Chronic Subdural Hematomas With Concurrent Antithrombotics. Neurosurgery 2023; 92:258-262. [PMID: 36480177 PMCID: PMC10553180 DOI: 10.1227/neu.0000000000002222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 08/31/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Chronic subdural hematoma (CSDH) is an increasingly prevalent disease in the aging population. Patients with CSDH frequently suffer from concurrent vascular disease or develop secondary thrombotic complications requiring antithrombotic treatment. OBJECTIVE To determine the safety and impact of early reinitiation of antithrombotics after middle meningeal artery embolization for chronic subdural hematoma. METHODS This is a single-institution, retrospective study of patients who underwent middle meningeal artery (MMA) embolizations for CSDH. Patient with or without antithrombotic initiation within 5 days postembolization were compared. Primary outcome was the rate of recurrence within 60 days. Secondary outcomes included rate of reoperation, reduction in CSDH thickness, and midline shift. RESULTS Fifty-seven patients met inclusion criteria. The median age was 66 years (IQR 58-76) with 21.1% females. Sixty-six embolizations were performed. The median length to follow-up was 20 days (IQR 14-44). Nineteen patients (33.3%) had rapid reinitiation of antithrombotics (5 antiplatelet, 11 anticoagulation, and 3 both). Baseline characteristics between the no antithrombotic (no-AT) and the AT groups were similar. The recurrence rate was higher in the AT group (no-AT vs AT, 9.3 vs 30.4%, P = .03). Mean absolute reduction in CSDH thickness and midline shift was similar between groups. Rate of reoperation did not differ (4.7 vs 8.7%, P = .61). CONCLUSION Rapid reinitiation of AT after MMA embolization for CSDH leads to higher rates of recurrence with similar rates of reoperation. Care must be taken when initiating antithrombotics after treatment of CSDH with MMA embolization.
Collapse
Affiliation(s)
| | - Hussein A. Zeineddine
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Michael I. Nahhas
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Matthew J. Kole
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Youngran Kim
- Division of Management, Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Hyun Woo Kim
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Salvatore A. D'Amato
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Peng Roc Chen
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Spiros L. Blackburn
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Gary Spiegel
- Department of Neurology, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Sunil A. Sheth
- Department of Neurology, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Ryan S. Kitagawa
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Mark J. Dannenbaum
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| |
Collapse
|